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CHAPTER 1. GENERAL INTRODUCTION 
Parkinson’s disease (PD) is associated with the degeneration of dopaminergic 
neurons in the substantia nigra (SN). One of the pathological hallmarks of PD is the 
presence of intracellular Lewy bodies (LBs). The soluble protein α-synuclein is 
expressed in presynaptic region and its aggregation is highly involved in the 
formation of LBs. Other factors that may also contribute to the progression of PD 
include: aging, genetic mutations, oxidative stress, environmental toxins, and 
inflammation. Among these factors oxidative stress has been considered the main 
factor in causing PD. Due to the high energy metabolism ratio and the structure of SN 
in normal brain, there is relatively high levels of basal oxidative stress. Postmortem 
studies and in vitro neuron studies demonstrate that elevated oxidative stress is linked 
to PD.  
Oxygen-generated free radical is the most important class which contributes to 
ROS and oxidative stress. The enzyme or metal-catalyzed process can directly or 
indirectly generate free radical. Current evidence shows the changes in the balance of 
redox transition metals are involved in free radical generation. Iron is an important 
trace element which participants in many physiological functions, such as 
neurotransmission and neuromelination. Many iron transporters and regulators are 
responsible for maintaining iron homeostasis. Iron can be up-taken via divalent metal 
transporter (DMT1), transferrin, and transferrin receptors (TfR). Ferrtin is responsible 
for iron chelation and storage; while ferroportin 1 (Fpn1) is used for iron exportation. 
Other regulators such as hepcidin and iron regulatory proteins (IRP) are also 
important in regulating the iron-related factors and maintaining the regular iron labile 
pool. Various factors can regulate iron transporters and cause iron dyshomeostasis 
including environmental toxins and genetic mutations. If iron dyshomeostasis occurs 
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it could exaggerate the generation of free radicals. The excess free radicals such as 
superoxides, can force enzymes to release free iron from iron-containing molecules. 
The neurotoxins 6-hydroxydopamine (6-OHDA) and 
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) act as the classic toxins to 
induce PD, and even though the mechanisms remain unclear they are still widely used 
in PD research. There is evidence that 6-OHDA releases iron from ferritin and the 
released iron can generate highly reactive hydroxyl radical via the Fenton reaction, 
consequently leading to neurodegeneration. Markers of oxidative stress in the SN 
which are reflected by enhanced lipid peroxidation, protein carbonyls, are confirmed 
in PD. In addition, the oxidative burst triggers inflammation, which is also involved in 
neurodegeneration. 
Several methods such as pharmacological treatments and surgical treatments can be 
used to treat PD. However, since the PD symptoms represent more than 50% neuronal 
cell death in SN, prevention methods are ideal ways for neuroprotection rather than 
the therapeutic methods. Prevention methods such as, antioxidation, antiinflammation, 
are considered as effective neuroprotection strategies. Attention is focused on the 
metal-induced formation of free radicals and the protective role of antioxidants 
(nuclear factor erythroid 2-related factor 2, Nrf2/antioxidant system), 
anti-inflammatory system (such as peroxisome proliferator-activated receptor γ, 
PPARγ) and flavonoids (catechins). The iron chelators, such as desferroxamine have 
shown to be effective in preventing or delaying PD progression. Epidemiological data 
shows the positive relationship between green tea consumption and the lowered risk 
of PD in Asian countries. In vitro and animal studies showed epigallocatechin gallate 
(EGCG) protected against 6-OHDA induced neurotoxicity. However, limited human 
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study data shows green tea as well as its main component EGCG directly protected 
against neurotoxicity.  
EGCG may benefit neurological disorders from several aspects: iron chelation, 
antioxidation, antiinflammation, and other pathway modulators. In this study we 
assessed the effect on iron homeostasis with6-OHDA induced neurotoxicity and the 
preventive effects of EGCG against neurotoxicity in N27 cells by attenuating reactive 
oxygen species (ROS) derived-oxidation and inflammation. We also show the 
beneficial effects of green tea consumption in PD patients. Our entire project contains 
three sets of studies. In the first study, we hypothesized that 6-OHDA and EGCG 
treatment would regulate iron related elements. We used dopaminergic N27 cells to 
determine the 6-OHDA induced dyshomeostasis by regulating iron transporter 
mRNAs and protein expressions, such as DMT1, Fpn1, and hepcidin. Meanwhile, 
EGCG protected against the adverse effects of 6-OHDA by normalizing and 
maintaining iron metabolism and homeostasis. In the second study, we showed the 
direct evidence that EGCG maintained the ROS homeostasis by suppressing 6-OHDA 
induced oxidative damage on lipids and proteins. We also conducted the preliminary 
study examining the stabilization of Nrf2 antioxidant system and PPARγ 
anti-inflammatory system by EGCG in N27 cells. In the third study, our hypothesis 
was to identify the beneficial effects of green tea consumption on PD patients, 
including slowing down the PD progression by improving the antioxidant status and 
reducing oxidative damage. We found out that the intervention might improve the 
quality of life of PD patients based on PD symptom rating scales and other measures 
as well as enhance the antioxidant status, reduce oxidative damage on lipids and 
proteins. We also showed that green tea intervention would not affect the iron status. 
All together these findings in this study reveal the importance of iron regulation and 
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oxidative damage in PD progression; the neuroprotection of EGCG by  its iron 
chelation, antioxidant, and antiinflammation capabilities in vitro, as well as beneficial 
effect of and green tea consumption  in PD patients.  
 
Dissertation Organization 
This dissertation is organized into six chapters, including a general introduction, a 
literature review, three chapters on research publications, and a final conclusion. 
Chapter 1 is a general introduction. Chapter 2 is a literature review of nutritional 
prevention on oxidative stress-associated PD. Chapter 3 and 4 are the manuscripts 
prepared to be submitted to Journal of Nutrition. Chapter 5 is manuscript prepared to 
be submitted to Movement Disorders Journal. Chapter 6 is the general conclusion of 
the studies which include the general conclusions and future directions. The 
references of this dissertation are formatted in the Journal of Nutrition requirement at 
the end of chapter 1 to 4. All the tables, figures, and legends in chapter 3, 4 and 5 are 
placed as close as possible to the original text references.  
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CHAPTER 2. LITERATURE REVIEW 
 
I. PARKINSON’S DISEASE 
Parkinson’s disease (PD) is the second most common neurodegenerative disease 
after AD, affecting approximately 1% of the population over 50 years old and causes 
an approximate $25 billion economic burden annually (1). PD is characterized by 
progressive loss of control over voluntary movement, which results primarily from the 
progressive loss of dopaminergic neurons in the SN, located in the mid-brain (2). The 
symptoms of PD include tremor, rigidity, bradykinesia, hypokinesia and akinesia. The 
pathological hallmarks of PD are the loss of the nigrostriatal dopaminergic neurons 
and the presence of intraneuronal proteinacious cytoplasmic inclusions, LBs. LBs are 
spherical eosinophilic cytoplasmic protein aggregates composed of numerous proteins, 
including α-synuclein, parkin, ubiquitin, and neurofilaments (4, 5). LBs are more than 
15 μm in diameter and have an organized structure containing a dense hyaline core 
surrounded by a clear halo. PD-associated loss of dopaminergic neurons is 
concentrated in ventrolateral and caudal portions of the SN, whereas during normal 
aging the dorsomedial aspect is affected. The striatal dopaminergic nerve terminals 
are the primary target of the degenerative process. Neurodegeneration and LB 
formations are found in noradrenergic, serotonergic, and cholinergic systems, as well 
as in the cerebral cortex, olfactory bulb, and autonomic nervous system. Degeneration 
of hippocampal structures and cholinergic cortical inputs contribute to the high rate of 
dementia related to PD, particularly in older patients. The disease is also considered 
as a tyrosine hydroxylase (TH) deficiency syndrome, since TH catalyzes the 
formation of L-3,4-dihydroxyphenylalanie, the rate-limiting step in the biosynthesis 
of DA in the striatum (6). In general, the appearance of disease symptoms is observed 
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after loss of 80% of striatal DA and 50% of the TH-immunoreactive dopaminergic 
neurons in the SN (7). 
 
A. Pathogenesis and Risk Factors of PD 
Major hypotheses related to the progressive loss of dopaminergic neurons are 
misfolding, aggregation of proteins, mitochondrial dysfunction, and the consequent 
oxidative stress, including toxic oxidized DA species. LBs consist of aggregates of the 
presynaptic soluble protein, α-synuclein. α-synuclein decreases mitochondrial 
complex I activity and increases ROS production (8). Oxidative damage can also 
interact with α-synuclein and enhance its misfolding. Moreover, multiple cell 
death-related molecular pathways are activated during PD progression, such as 
apoptosis and necrosis. 
 
1. Age 
Age has been considered a potential risk factor for PD because most patients 
develop PD after 50 years of age. The incidence of PD increases markedly over age 
55, with a 20/100,000 incidence at age 55 to a 120/100,000 incidence at age 70 (3). 
Pathologically, aging is associated with a decline of pigmented neurons in the SN. It 
is also suggested that the aging nigrostriatal system may be more vulnerable to 
damage by exogenous and endogenous toxins since the neurotoxin MPTP causes 
more severe pathological and neurochemical injury in older mice (9). 
 
2. Genetic Susceptibility 
Common sporadic PD shares similar phenotype with genetic forms of PD, and the 
same pathogenic and genetic mechanisms help to clarify the key biochemical pathway 
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of PD progression. These PD genes that have been identified and studied in some 
detail: α-synucelin, parkin, and ubiquitin c-terminal hydrolase L1 (UCHL1) appear to 
participate in the ubiquitin-proteasome system (UPS), affecting protein clearance and 
cause LBs protein aggregation, which is the characteristic of PD neuropathology. In 
addition, familial PD genes, such as PTEN-induced putative kinase 1 (PINK-1), DJ-1 
or dominant Leucine-Rich Repeat Kinase 2 (LRRK2) are closely related to the 
impairment of mitochondrial complex I.   
 
3. Environment  
Several epidemiological studies have suggested that exposure to different 
environmental agents including pesticides, insecticides, heavy metals, and microbial 
toxins may increase the risk of PD (10, 11). A byproduct of an illicit narcotic drug, 
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) as well as its metabolite MPP+, 
has been shown to cause the same signs and symptoms as PD. As mitochondrial 
poisons, rotenone, and paraquat also activate the progression of PD. Human 
epidemiological studies have implicated a higher incidence of PD in residents of rural 
environments with exposure to herbicides and pesticides (12). However, cigarette 
smoking and coffee drinking are inversely associated with the risk for development of 
PD (13), reinforcing the concept that some environmental factors do modify PD 
susceptibility. 
 
4. Inflammation 
Inflammation has also been implicated in the pathogenesis of PD. 
Pro-inflammatory cytokines such as interleukin-1β (IL-1β) and tumor necrosis 
factor-α (TNF-α) may induce microglia activation and cause microglia related to 
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neuronal injury (14). The negative association between the low risk of PD and high 
anti-inflammatory activities indicates the role of inflammation in PD progression, and 
suggests anti-inflammatory therapy as a potential neuroprotective strategy. 
 
5. Oxidative Stress 
Although environmental, genetic, and inflammatory factors contributed to the 
etiology of PD, oxidative stress has been confirmed to play the main role in PD 
progression (14). Brain tissue is susceptible to oxidative stress since it is rich in 
polyunsaturated fatty acids, which can easily undergo lipid peroxidation. In addition, 
high levels of ATP consumption in the brain could cause high oxidative metabolism 
as the electrons might leak to form oxygen free radicals. The features of enhanced 
oxidative stress linked with PD are supported by both postmortem studies and by 
studies showing oxidative stress inducing nigral cell degeneration (15, 16). The 
factors, including an impairment of antioxidant status, such as reduced glutathione 
(GSH), increased reactive species, augmented DA oxidation, and high iron levels, 
which are associated with oxidative stress, have also been found in the SN in PD (17). 
 
B. Animal Models of PD 
6-OHDA administration is widely used to induce PD in animal models, especially 
in rats (19-21). 6-OHDA impairs sympathetic neuron nerve terminals in the peripheral 
nervous system when administered systemically. Due to its chemical similarity with 
catecholamine, it has a high affinity for the catecholamine transporter and is able to 
damage the catecholaminergic neurons (22). Different from systemic administration 
of MPTP, 6-OHDA only partly crosses the blood brain barrier (BBB). Brain injection 
into the SN is one main way to kill TH-positive neurons, causing a dose-dependent 
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loss in DA in the central nerve system (CNS) (23). Mice with 6-OHDA lesions in the 
medial forebrain bundle (MFB) indicate the dose-dependent manner of damage on 
midbrain DA neurons (30). Lundblad (2004) reported the first 6-OHDA lesioned mice 
developing dyskinesia, which was similar to those previously characterized in the rat 
and in other animal models of PD (31) and PD patients (32, 33). Compared with the 
corresponding rat model, MFB-lesioned mice show a much larger number of 
TH-positive cell bodies in the striatum. However, the functional importance of these 
neurons is yet to be clarified. 
 
C. Cell Models of PD 
Cell cultures, such as mesencephalic slice cultures, primary immature 
dopaminergic neurons, and immortalized cell lines, either in a proliferating state or in 
a differentiated state, are used for the screening of pathogenesis and drug candidates 
in PD research (39). The loss of TH+ immunoreactivity is used as a marker in primary 
neuron model cells, and neurotoxins, including 6-OHDA and MPP+, can cause 
significant TH+ cell death (40-42). The difficulty in producing the primary 
mesencephalic neuron cells in large quantities limits their usefulness even if they have 
the physiological characteristic of neurons of the SN. The catecholaminergic 
neuroblastoma cell lines, such as SH-SY5Y, have been used to clarify the proposed 
mechanisms of 6-OHDA and MPTP neurodegeneration in PD, including oxidative 
stress and inflammation (43-45). The SH-SY5Y cells are less sensitive to neurotoxins 
since they are not neuronal cells. N27 cells are from an immortalized line derived 
from the rat mesencephalon, and may be more physiologically similar to 
dopaminergic neurons. N27 cells can express both tyrosine hydroxylase and the DA 
transporter, and produce measurable amounts of DA (46). N27 cells are sensitive to 
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6-OHDA and can help to clarify the 6-OHDA induced neurotoxicity. The MN9D cell 
line, a fusion of embryonic ventral mesencephalic and neuroblastoma cells, is 
extensively used as a model of DA neurons because they express tyrosine hydroxylase 
and can synthesize and release DA. These cells are also used to understand the 
mechanisms and to develop potential therapeutics to prevent DA neuronal loss in PD 
research (47). 
Non-dopaminergic cell lines, such as CHO-K1 and HEK293 are also used for 
studying PD (48, 49).  The PC12 cell line, a rat pheochromocytoma cell line, has 
been extensively used as a tool for studying the function of neurotrophic factors and 
neuronal differentiation, and is widely used as a model cell to study the environmental 
effects, oxidative stress, and genetic manipulation on PD progression (50). Several 
studies showed that 6-OHDA induced PC12 cell death by oxidative stress, cell 
apoptosis, and necrosis in a pro-inflammatory manner (50, 51) . 
There are still several other cell lines, such as peripheral T-lymphocytes, that can 
be used to study the inflammatory and cell apoptotic pathways during PD progression 
(52). 
 
D. Mechanism of 6-OHDA-induced Neuron Cell Damage 
Neurotoxins are shown to depolarize the mitochondrial membrane potential, disturb 
the mitochondrial function, inhibit the ubiquitin proteasome system (UPS), and 
decrease proteasomal function (53-55). Consequently, they cause ubiquitinated 
protein accumulation in the mitochondria, such as α-synuclein, resulting into a 
reduced activity of mitochondrial complex I, and increase influx of Ca
2+
 into the cell, 
causing an excitotoxic condition (56). 6-OHDA has been shown to reversibly inhibit 
both mitochondrial complexes I and IV activities in rat brain with inhibition 
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concentration (IC50) of 10 and 34 µM (57-59). 6-OHDA is mechanistically similar to 
DA, binding to DA receptors on neuropeptide substance P (SP)-containing striatal 
projection neurons, releasing SP.  SP can then potentiate both DA and glutamate 
release to cause oxidative stress and glutamate excitotoxicity, contributing to 
dopaminergic cell death (60). In addition, 6-OHDA is also subjected to auto-oxidation 
to generate ROS, including quinines, hydrogen peroxide, superoxide radicals, and 
hydroxyl radicals (61). It has been shown in vitro that DA reacts with Fe (II) in the 
presence of hydrogen peroxide to generate 6-OHDA (62). 6-OHDA can then react 
with ferritin to cause iron release and subsequent cellular damage (63). 6-OHDA also 
induces NO and iNOS over-expression, cell apoptotic and necrotic cell death, and 
pro-inflammatory gene (IL-1B, TNF-a, COX-2) activation (50, 51, 64).  
The molecular pathways involved in 6-OHDA-induced cell death have also been 
studied in vivo, however less is known about the mechanism of progressive 
dopaminergic neuronal death by the striatal injection of 6-OHDA. 6-OHDA activates 
NF-κB, p53 and the c-jun N-terminal kinase (JNK) pathway, which has been 
identified in dopaminergic cell death in both the MFB and the striatal model (65, 66). 
In addition, the anti-inflammatory PPARγ was shown to attenuate 6-OHDA toxicity 
in a rat model, indicating the involvement of an inflammatory reaction. More recently, 
6-OHDA has been shown to elevate the activation of an apoptosis signal regulating 
kinase 1 (ASK1), indicating the oxidative stress and apoptotic pathways in PD 
progression (47). 
 
II. OXIDATIVE STRESS AND NEURODEGENERATION 
Oxidative stress can result from a variety of conditions that represent either 
increased ROS production or a decreased antioxidant defense. The superoxide radical 
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is considered as the “primary” ROS, which further generates “secondary” ROS by 
interacting with other molecules. For example, hydrogen peroxide can be generated 
by a dismutase reaction. The superoxide dismutase (SOD) enzyme also works in 
conjunction with other H2O2–removing enzymes, such as catalase and glutathione 
peroxidase (GPx). The production of H2O2 and O2 is tightly linked with the 
participation of redox-active trace metals. 
 
The redox states should be maintained within strict physiological limits. In vivo, 
under stressed conditions, an excess of superoxide acts as an oxidant of [4Fe-4S] 
cluster-containing enzymes, releasing “free iron” from iron-containing molecules. The 
released Fe
2+
 can participate in the Fenton reaction, generating highly reactive 
hydroxyl radicals (67). Cells of the immune system also produce both the superoxide 
anion and nitric oxide during the oxidative burst triggered during inflammatory 
processes. Under these conditions, nitric oxide and the superoxide anion may react 
together to produce significant amounts of a much more oxidatively active molecule, 
such as peroxynitrite anion (ONOO-) (68, 69).  
The oxidation of cellular components by oxidative stress results in modifications of 
DNA, proteins, lipids, and carbohydrates, which are associated with cell death either 
by necrosis or by apoptosis. 4-hydroxy-2-nonenal (HNE) is the main aldehyde 
by-product formed during lipid peroxidation, and considered to be one of the most 
reliable markers of oxidative stress. Protein carbonylation is the ROS-induced 
post-translational modification of amino acid side chains. The protein carbonyl is 
widely used as marker of oxidative protein damage (70, 71). In addition, lipid 
peroxidation can also exacerbate the oxidation of protein. Some protein carbonylation 
from lipid-derived aldehydes is more prevalent than that formed via direct amino acid 
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side chain oxidation (72). ROS can also attack DNA, generating DNA lesions and 
resulting in mutagenesis and cell death, especially in the progression of DNA/RNA 
polymerases. 
Nigral dopaminergic neurons are particularly exposed to oxidative stress due to the 
high monoamine oxidase (MAO) enzyme activity which yields H2O2 and other ROS. 
H2O2 could also react with iron in the SN to produce highly toxic hydroxyl radicals. 
The auto-oxidation of DA can also acerbate the ROS level (73). Due to the 
significantly lower concentration of antioxidants in the brain compared with other 
organs (74, 75), the brain is much more sensitive to oxidative stress. Previous work 
has shown that neurodegeneration is closely related to increased ROS levels in brain. 
Postmortem brains of PD patients have shown high levels of oxidation of lipids, 
proteins, and nucleic acids in the SN. The loss of functional nicotinic acetylcholine 
receptors (nAChRs) in neuron cells due to the intracellular ROS is like to have 
significant implications for the early progression of PD (76-78), therefore oxidative 
stress is directly involved in the loss of dopaminergic nigral neurons.  
 
A. Oxidative Stress and Mitochondrial Dysfunction 
There is considerable evidence for mitochondrial dysfunction in the brain of PD 
patients (79, 80). The dramatic loss of function of mitochondrial complex I activity 
may be the central tenet of sporadic PD, consequently promoting oxidative stress. 
Damage to mitochondrial complex I by oxidative stress can be acerbated by trace 
metals, environmental toxins, and familial Parkinson related genes. Epidemiological 
studies showed MPTP is related to acute and irreversible Parkinsonism in human and 
non-human primates (81). Different from 6-OHDA, MPTP is a lipophilic molecule 
that can easily cross the BBB and be transferred to 
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1-methyl-4-phenyl-2,3-dihydropyridinium (MPDP) in glial cells and metabolized to 
the active toxic compound (MPP+, 1-methyl-4-phenylpyridinium) (82). MPP+ can be 
taken up by DA neurons and concentrated in mitochondria, causing complex I 
dysfunction and oxidative stress (83). MPTP is responsible for several downstream 
apoptotic events in SN neurons, including up-regulation of inflammatory factors, 
release of cytochrome c, and activation of caspase-3 activity. In addition to MPTP, 
pesticides with related properties, such as rotenone, paraquat, dieldrin, and maneb 
exhibit common features to inhibit the mitochondrial respiratory chain and produce 
oxidative stress (84, 85).  
Significant evidence suggests that accumulation of α-synuclein in mitochondria 
elevates oxidative stress, which is relevant to PD pathogenesis. Complex I defects 
cause α-synuclein aggregation and this aggregation would lead to further 
mitochondrial dysfunction, such as decreased mitochondrial membrane potential, and 
oxidation of mitochondrial proteins (86, 87). Further studies are needed to elucidate 
the precise functions of α-synuclein in the regulation of mitochondrial functions. 
Additionally, other genes linked to familial PD have been implicated in the 
mitochondrial function and oxidative stress response.  
 
B. Metal Related Neurodegeneration, With Particular Consideration of Iron 
Over the last decade, the redox ability of metal ions, such as copper, has been 
shown to lead to radical formation, and reactive nitrogen and oxygen species, 
contributing to various diseases. These metals can be coupled with proteins, 
accelerating the electronic reactions. A number of recent studies showed that 
α-synuclein interacts with zinc, copper, and iron, consequently in the state of 
aggregation (88). Therefore, it has become widely accepted that dyshomeostasis of 
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these redox metal ions (manganese, copper, iron, lead, and aluminum) is accompanied 
by oxidative stress, which is a key factor in a large number of neurodegenerative 
diseases, such as PD, Alzheimer’s disease, Hungtington’s disease, multiple sclerosis 
and Friedreich’s ataxia (89). It has been shown that the concentration of zinc and iron 
are increased and copper is decreased in the SN in PD. However, the mechanisms of 
these changes remain unclear. Iron accumulation is closely related to 
neurodegenerative diseases. The elevation of brain iron such as in the putamen, motor 
cortex, sensory cortex and thalamus, are localized within H- and L-ferritin and 
neuromelanin with no adverse effects (90). However, excessive iron in cellular 
constituents, like the mitochondria, or specific regions, such as SN and lateral globus 
pallidus, can lead to the generation of toxic free radicals which can damage cells (89). 
Numerous studies have confirmed that there is an elevated iron level in the SN of PD 
patients compared to age-matched controls (91, 92). The oxidative stress in brain 
regions can cause peroxidation of polyunsaturated fatty acids in membrane 
phospholipids, generating protein carbonyls and damaging neurons. 
 
C. Brain Iron and Neurodegeneration 
Iron is a necessary cofactor in many metabolic processes in the central nervous 
system, including oxidative phosphorylation, myelin synthesis, nitric oxide 
metabolism, and oxygen transport. It plays an important role in electron transfer and 
affects numerous enzymes, including a number of key enzymes for neurotransmitter 
biosynthesis in the brain, such as tyrosine hydroxylase, which is involved in the 
metabolism of DA (93).  
Serum iron is delivered to cells via transferrin (Tf). Endothelial cells can express 
transferrin receptor (TfR) on the luminal side of the capillaries in the BBB, and serum 
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iron can be delivered into the brain via the transferrin (Tf)-TfR-cell model, which is 
regulated by astrocytes. The iron which was in a diferric form in transferrin (Fe
2+
-Tf) 
binds to TfR, followed by receptor-mediated endocytosis, therefore iron can be 
transported from the luminal to the abluminal sides of the blood capillary endothelial 
cells (BCECs). Later, iron is released from transferrin within the endosome under the 
acidic pH environment and the apotransferrin is recycled back to the plasma 
membrane to bind to more iron. DMT1 is responsible for transporting iron in and out 
of the endosome into the cytoplasm, and then metalloreductases can reduce Fe
3+
 to 
Fe
2+
. Therefore, cytoplasmic iron can be transferred to the mitochondria for biological 
usage, while the extra iron is stored in cytosolic ferritin (94, 95). Astrocyte cell 
membranes contain ceruloplasmin (Cp) which is linked to glycophosphoinostitide 
(GPI) (96). The ferroxidase activity of GPI-Cp is required for the stability of Fpn1 in 
cells, facilitating the iron efflux from the cells (97). Fpn1 is present in neurons and 
could therefore represent the mechanism by which iron is exported from such cells 
(98). Additionally, another iron regulator, hepcidin, is responsible for regulation of 
iron homeostasis. Hepcidin can bind to Fpn1 and down-regulate Fpn1 mRNA and 
protein expression by inducing its internalization and degradation, promoting iron 
retention (99). Hepcidin is expressed in several organs, such as liver and brain, and is 
closely related to the increased iron. It is also considered as an oxidation indicator, 
associated with oxidative stress.  
Overall, iron metabolism and iron homeostasis at both the cellular and systemic 
levels is mainly regulated by the iron-associated proteins, such as ferric reductase, 
DMT1, the iron exporter Fpn1, and the membrane-bound ferroxidase. The translation 
of these proteins is modulated by the IRP system, together with the other iron 
homeostasis regulators, including hepcidin.   
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Fig. 1 The iron uptake into cell. Holotransferrin (HOLO-TF) binds to transferrin receptors (TFR) at the 
cell surface. The complexes localize to clathrin-coated pits, which initiate endocytosis. Specialized 
endosomes form and are acidified by a proton pump. At acidic pH, iron is released from transferrin and 
is co-transported with protons out of the endosomes by the divalent metal ion transporter DCT1. 
Apotransferrin (APO-TF) bound to TFR is returned to the cell membrane, where, at neutral pH, they 
dissociate to participate in further rounds of iron delivery. In non-erythroid cells, iron is stored as 
ferritin and hemosiderin (89). 
 
IRPs are the key factors to post-transcriptionally regulate the iron-associated 
proteins involved in cellular iron metabolism. IRP1 and IRP2 also function as 
cytosolic iron sensors. In conditions of iron deficiency, IRPs bind with IRE, which is 
in the 5’-untranslated regions of the mRNA, preventing initiation of translation of 
ferritin and Fpn1. In contrast, in the case of transferrin receptor and DMT1 where the 
IREs are in the 3’-untranslated region, binding of the IRPs to the mRNAs protects 
them against degradation by nucleases. Therefore, this leads to increased iron uptake 
and reduced iron storage and export. In conditions of iron abundance, the IRPs are no 
longer active in binding, allowing ferritin and Fpn1 mRNA to be translated and 
inhibiting iron uptake by reducing transferrin receptor and DMT1 synthesis.  
Disruption of iron transport proteins could cause excess iron in the brain. The cause 
might be genetic or by neurotoxins. The interruption of iron homeostasis is involved 
in a number of neurodegenerative disorders, including PD. The main adverse effect of 
18 
excess iron is the production of highly reactive hydroxyl radicals via the Haber-Weiss 
and Fenton reactions (100): 
 
If the increased ROS levels exceed the capacity of the self-antioxidant defense 
system, the cells will experience oxidative stress, membrane oxidation and protein 
damage. Increased oxidative stress is one of the contributors to PD progression. In 
addition, oxidative stress also exacerbates the intracellular free iron level, further 
promoting the α-synuclein aggregation to form LBs in PD brains (101).  
Even if the iron dyshomeostasis is related to neurological diseases, it is still under 
debate whether impaired iron homeostasis is the primary cause. Genetic 
hemochromatosis and thalassemic patients with high circulating iron, transferrin 
saturation, and high levels of low-molecular weight iron, do not exhibit increased 
brain iron. Evidence shows that higher iron distribution in different brain regions was 
associated with pathologic status.  
 
D. Oxidative Stress and Neuroinflammation in PD 
The immune responses within the brain are regulated by resident immune cells. 
Microglia are the major resident immune cells in the brain, providing innate immunity 
via the production of neurotoxic factors including cytokines, chemokines, and 
prostaglandins. Those factors also contribute to the immune activities of surrounding 
astrocytes and oligodendrocytes (102). Pro-inflammatory cytokines such as TNF-α 
and IL-1β act on astrocytes, inducing the adaptive immune response, while 
chemokines such as monocyte chemotactic protein-1 (MCP-1)/Chemokine (C-C motif) 
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ligand 2 (CCL2) recruit additional immune cells. These inflammatory responses may 
potentiate neuronal cell damage through oxidative stress. Neuroinflammation and 
oxidative stress share common linkages and influence each other. One of the 
functions of proinflammatory cytokines is to produce oxidative stress, which can 
subsequently shape the profile of cytokine release. Microglia are a major source of 
ROS in the CNS. Under the pathologic condition where there is reduced antioxidant 
level, oxidative stress causes more free radicals to be released into the cytosol, 
inactivating proteins or interrupting intracellular signaling pathways. In addition, ROS 
can initiate pro-inflammatory pathways in neuronal cells. Compared to cortical or 
hippocampal neurons, midbrain DA neurons are more susceptible to 
pro-inflammatory cytokines such as TNFα (103). Therefore, future therapeutic 
interventions to limit the early pro-inflammatory response would be beneficial in 
reducing microglia activation and elevated oxidative stress (104).   
Epidemiological, animal and human studies implicated the innate and peripheral 
neuroinflammatory response contributing to the onset of PD. Increased immune cells, 
such as CD4+ and CD8+ have been found in post-mortem human PD brains (105, 
106). The use of positron emission tomography (PET) imaging has confirmed the 
activated microglia in human PD brain (107). Elevated levels of pro-inflammatory 
cytokines have been found in the SN of PD brains. Factors known to promote 
neuroinflammatory response, including traumatic brain injury, and exposure to 
viruses and infectious agents, have all been proposed as increased risk factors for 
developing PD (108). In addition, 6-OHDA and MPTP are also commonly shown to 
cause PD in animal models, and display features of neuroinflammation.  
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1. Antioxidation  
Peroxisome proliferator receptor (PPAR) is a family of ligand-dependent nuclear 
hormone receptor transcription factors that play a key role in the regulation of 
inflammatory responses, antioxidation, and brain function. PPARs stimulate gene 
expression by binding to peroxisome-proliferator response elements (PPREs) of the 
target genes (109). There are three structurally homologous iso-types: PPARα, 
PPARβ/δ, and PPARγ. PPARα is expressed in several organs, including liver, kidney, 
intestine, heart, skeletal muscle, and brain. PPARα is involved in acetylcholine 
metabolism, excitatory neurotransmission, and oxidative stress defense. PPARα can 
regulate lipid metabolism and energy homeostasis (110). PPARβ/δ is ubiquitously 
expressed in all cell types, including immature oligodendrocytes, and promotes 
differentiation and myelination in the CNS. PPARβ/δ also can regulate lipid 
metabolism in the brain (111). PPARγ can be detected in adipose tissue, intestinal 
mucosa, retina, skeletal muscle, heart, liver, and lymphoid organs. PPARγ has been 
implicated in the pathology of numerous diseases including obesity, diabetes, 
atherosclerosis, and cancer. PPARγ is not only an anti-inflammatory factor, but also 
has antioxidant properties, and is used as treatment of oxidative stress related diseases, 
including PD, AD, and multiple sclerosis (112, 113). In these disorders, PPARγ 
agonists have the potential to modulate various signaling pathways, including matrix 
metalloproteinase-9, mitogen-activated protein kinases (MAPK), signal transducer 
and activator of transcription, mitochondrial uncoupling protein 2, and amyloid 
precursor protein degradation (114). PPARγ may directly modulate the expression of 
several antioxidant genes in response to oxidative stress, including catalase, SOD, 
GPx, the scavenger receptor CD362, and nitric oxide synthase (eNOS) (115-119). 
PPARγ can regulate heme oxygenase-1 (HO-1) expression, however this effect is still 
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under debate (120, 121). It is obvious that PPARγ is closely related to antioxidative 
defense mechanisms. Recent evidence had confirmed that Nrf2 and PPARγ were 
linked by a positive feedback loop that sustained the expression of antioxidant genes 
and antioxidant system under oxidative stress (119, 122). Therefore, antioxidation and 
anti-inflammatory pathways might be simultaneously involved in the progression of 
neurodegeneration and the clarification of the mechanisms on the interaction will be 
needed to be researched. 
 
2. Anti-inflammatory System 
The neuroinflammatory diseases, including AD, and PD, present major challenges 
to the health care system and impose substantial economic costs around the world 
(123). Since evidence shows that PPARγ is expressed in certain areas of the brain, 
such as neurons and glial cells, it may possibly be involved in neuroinflammation and 
subsequent neurodegeneration. As shown in a MPTP model, PPARγ exerts both 
anti-inflammatory and antioxidant effects by inhibiting glial activity, which may 
account for the attenuation of dopaminergic cell loss in both the SN and striatum. In 
the LPS-induced inflammatory model of PD, PPARγ showed the ability to restore 
striatal DA, mitochondria function, and significant dopaminergic neuroprotection by 
directly inhibiting mitochondrial fatty acid metabolism and altering mitochondrial 
uncoupling protein expression (124, 125). 
PPARγ could reduce the infiltration of immune cells to the BBB and down-regulate 
pro-inflammatory genes such as COX-2, iNOS, and various cytokines, which were 
associated with inflammation-induced neurodegeneration (126-128). The 
neuroprotection of PPARγ activation was also based on antiinflammation through 
inhibiting IL-6, TNFα expression, and toll-like receptor (129, 130).  
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Additionally, epidemiological studies showed that 7% of PD patients have type II 
diabetes or insulin desensitization. They suggest that diabetes accelerated the 
progression of the motor and cognitive symptoms of PD, and insulin in the 
nigrostriatal system is related to PD (131). Drugs used to treat PD, such as L-dopa or 
bromocriptine alter insulin signaling and sensitivity. PPARγ had been associated with 
insulin sensitivity alteration and inhibition of inflammation. Therefore, PPARγ 
activation may offer a new clinical treatment approach to neuroinflammation and PD 
(132).  
 
III. TREATMENT AND PREVENTION STRATEGIES OF PD 
Since it is impossible to cure PD, preventing and controlling the symptoms of PD 
and minimizing side effects are the goals of anti-Parkinsonian therapy. Data is lacking 
in many areas of PD treatment and prevention, therefore, there is currently wide 
variation in the management of PD. 
 
A. Treatments 
1. Pharmacological Treatment 
L-dopa has been used as the main pharmacological treatment of PD, and peripheral 
decarboxylase inhibitor is used to limit metabolism of L-dopa. Even if L-dopa is the 
most effective drug in the treatment of PD, long-term use can cause motor 
fluctuations and dyskinesias (133). There is still debate over how to use L-dopa as a 
neurological treatment, such as dosage and time. L-dopa has been shown to be toxic 
to neurons in vitro, but these findings have not been substantiated in humans (134, 
135).  
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DA agonists are frequently used as adjunct therapy with L-dopa in early PD, and 
they include bromocriptines, pergolide, lisuride, cabergoline, pramipexole and 
ropinirole. The mechanism of action of DA agonists depends on their DA releasing, 
inhibiting reuptake and DA receptor and stimulating capabilities. Monoamine oxidase 
B (MAO-B) inhibitors can be used as dopaminergic therapy in patients with early PD 
because they can inhibit DA catabolism and increase nigrostriatal DA levels. The 
inhibition of catechol O-methyl transferase (COMT) can increase the bioavailability 
and prolong the action of DA and is also considered as a therapy for neuroprotection. 
In addition, anticholinergic medication methods are also used to treat PD, such as 
benztropine and procyclidine. However, they are typically used in younger PD 
patients, instead of patients older than 65.  
 
2. Surgical Treatment 
Recognition of the limitations of pharmacological therapy and improvement in 
surgical technologies has led to a resurgence of surgery on PD patients in recent years. 
Even though surgical treatment may raise concerns regarding safety, it may reduce 
drug-induced dyskinesias and dystonias in PD, including ablative procedures (globus 
pallidus or thalamus), deep brain stimulation and tissue transplant (136). Thalamic 
stimulation has equal efficacy for tremor suppression, but with fewer adverse effects 
compared to thalamotomy (137). Transplantation has shown promising benefits, but 
studies are questioning its efficacy and safety, which has impeded this treatment 
procedure (138). 
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B. Prevention Strategies 
Due to the efficacy and safety concerns about the treatment therapies of PD, the use 
of antioxidants, anti-inflammatory drugs, and specific stress signal inhibitors as 
prevention methods have provided potential beneficial effects for common 
neurodegeneration.  
 
1. Antioxidants  
Selegiline, vitamin E, and rasagiline have been used in clinical trials due to their 
antioxidant properties (139, 140). Selegiline reduces DA oxidation by inhibiting 
MAO-B and has been used as an antioxidant drug. Although there exist concerns 
about the efficacy of vitamin E in the prevention of PD, long-term, high dose vitamin 
E dietary supplementation (e.g. 1600-2000 IU d-α-tocopheryl succinate) was shown 
to be a successful therapeutic strategy for the prevention of PD (143, 144). Rasagiline 
is a newer MAO-B inhibitor and its metabolite has potential antioxidant property. A 
clinical study showed rasagiline reduced the oxidative effect of symptomatic efficacy. 
Coenzyme Q10 (CoQ10) is a cofactor in the electron transport chain in mitochondria 
metabolism and has been shown to reduce dopaminergic neurodegeneration in mouse 
PD models (145). However, CoQ10 showed less or no significant protection on PD 
progression based on different study designs, initiating concerns on the stability of its 
usefulness (146-148). Even if none of these clinical studies have convincingly shown 
that these antioxidant therapies slow disease progression, several of these trials 
indicate that selegiline, rasagiline, and CoQ10 may be promising. In addition, 
compared to current PD treatments, all of the antioxidant approaches are relatively 
safer in neuroprotection. Epidemiological studies identified uric acid as a potential 
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neuroprotective agent in PD, which acts as an antioxidant by scavenging ROS and 
NOS.  
 
2. Receptor antagonists 
Epidemiological studies have shown that caffeine may reduce the incidence of PD, 
leading to adenosine receptor antagonists as potential neuroprotective agents (13, 153). 
Adenosine receptor antagonist A2a can improve symptoms in PD and be 
neuroprotective, which was shown in several in vivo studies (154, 155). A2a can also 
exert synergistically effects with L-dopa (156).  
DA receptor agonists have been proposed as potentially neuroprotective by acting 
at D2 autoreceptors found on dopaminergic SN terminals to suppress DA release and 
thus reduce oxidative stress in vitro and in animal studies (157-160). Certain agonists, 
such as pramipexole, may also act as direct antioxidants due to their hydroxylated 
benzyl ring structure. However, it is still difficult to establish long-term systems for 
neuroprotection of the receptor antagonists’ neuroprotection. 
 
3. Anti-inflammatory agents  
The use of anti-inflammatory drugs has been investigated in various diseases. In 
PD, antiinflammation has been considered as a potential neuroprotective strategy in 
drug development (161). Anti-inflammatory agents, including non-steroidal 
anti-inflammatory drug (NSAIDs) and minocycline have been used to treat PD in 
tissue culture and in animal models. NSAIDs, such as aspirin, have anti-inflammatory 
effects, including reduction of TNFα, nitric oxide, and superoxide production by 
microglia (162). Statins may also act to show neuroprotection due to their 
anti-inflammatory ability beyond scavenging free radicals (163). Epidemiological 
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studies showed that statin use, particularly simvastatin, was associated with reduced 
PD incidence (164, 165). Simvastatin had been shown to reduce DA loss in MPTP 
animal models (162). Minocycline has anti-inflammatory effects independent of its 
antimicrobial activity and protects against dopaminergic cell loss in both MPTP and 
6-OHDA animal models (166, 167). Minocycline blocks microglial activation and 
may also have anti-apoptotic activity in vitro (168).  
 
4. α-synuclein-directed therapies 
Since protein aggregations, like α-synuclein, are related to PD progression, the 
disruption of α-synuclein aggregation has been the focus of research to develop novel 
therapies against PD. Augmentation of parkin or ubiquitin carboxy-terminal 
hydrolase-L1 (UCH-L1) activity could promote the clearance of α-synuclein and 
other aggregated proteins (169, 170). Activation of lysosomal degradation could also 
clear α-synuclein. Therefore, the lysosomal enzyme cathepsin D could inhibit 
α-synuclein-induced neurotoxicity in cell culture and animal models (171). Because 
oxidative modification and phosphorylation of α-synuclein both promote protein 
aggregation, antioxidants and kinase inhibitors could reduce α-synuclein aggregation 
and toxicity (172-174). In addition, direct blockers of α-synuclein aggregation could 
be a therapeutic strategy for PD. Increasing the expression of chaperone-like proteins, 
such as 14-3-3, has been demonstrated to reduce α-synuclein aggregation and could 
serve as a basis for therapeutic intervention (175, 176). The chaperone protein Hsp70 
reduced insoluble α-synuclein aggregates in vitro and in vivo (177). 
The COMT inhibitors entacapone and tolcapone are able to block fibril formation 
of α-synuclein. However, a strong limitation for the use of these compounds is that 
they have a wide range of side effects, such as vomiting, nausea and hypotension, or 
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in the case of tolcapone, hepatotoxicity (178). In addition, cholesterol reducing agents 
have been shown to be effective in blocking α-synuclein aggregation in vitro and in 
vivo. 
 
5. Anti-apoptotic agents 
Several anti-apoptotic agents have been examined in controlled clinical trials. 
Vasoactive intestinal peptide (VIP) can be considered as a good anti-apoptotic 
candidate agent for 6-OHDA induced neurotoxicity and the treatment of PD (179). 
Tauroursodeoxycholic acid (TUDCA) acts as an anti-apoptotic agent in MPTP mouse 
PD models, used as a modulator of neurodegeneration in PD (180). The 
propargylamine TCH346 is an anti-apoptotic factor and was shown in both 6-OHDA 
and MPTP animal models to reduce dopaminergic cell loss (181, 182). Overall, 
anti-apoptotic agents would be a perspective treatment for PD progression. 
 
6. Kinase inhibitors 
The activation of kinase pathways has been shown to be involved in the 
progression of PD in in vitro and in vivo studies. The most common genetic cause of 
PD to date is mutation in the gene LRRK2, which is associated with increased kinase 
activity. Therefore, kinase inhibitors seems to be new neuroprotective strategies 
against the progression of PD. Kinase inhibitors, such as 
Z-Asp(Ome)-Ile-Pro-Asp(OMe)-FMK can block PKCΔ cleavage and reduce 
caspase-3 related neurotoxicity. It can also rescue TH+ neurons from MPP+ and 
6-OHDA-induced toxicity in primary mesencephalic cultures (183). 
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7. Polyphenols 
Polyphenols are a class of highly bioactive compounds, and can be categorized into 
flavonoids, stilbenes, phenolic acids, phenolic alcohols, and lignans. A number of in 
vitro and in vivo studies indicate that these small molecules are able to modulate 
neurological progression pathways due to their strong antioxidant and 
anti-inflammatory effects. A natural polyphenol resveratrol can directly scavenge the 
hydroxyl radical, inhibit H2O2 or lipid peroxide-dependent peroxidation (190, 191), 
suppress COX-2-induced neuroinflammation (192), and reduce dopamine-induced 
cell death in vitro (193, 194). In vivo, resveratrol attenuated 6-OHDA-induced DA 
depletion and loss of dopaminergic neurons in rats (195). 
It is important to note that many in vitro studies have focused on the 
neuroprotective properties of flavonoids that differ from their forms in vivo. For 
example, natural forms of flavonoids are hydrolyzed and conjugated by gut and liver 
enzymes before entering the circulation (196), resulting in reduction of their 
antioxidative activity (197, 198). Both intact and derivative forms of flavonoids such 
as tea catechins and naringenin have been found to pass through the BBB (199). The 
degree of permeability is governed by several factors, including compound 
lipophilicity and the action of specific transporters on the BBB (200). Therefore, 
elevating the bioavailability of flavonoids in CNS would benefit PD drug 
development. 
 
8. Nutritional strategies 
Oxidative stress causes the loss of dopamine neuron within the central nervous 
system. Therefore, an antioxidative has to potential to impart neuroprotection. A diet 
containing high levels of antioxidants, such as complex phenols, vitamin E, and 
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carotenoids, acts as a preventative measure for the disease. Higher intake of 
vegetables, legumes, fruits, cereals, unsaturated fatty acids, and fish may add more 
antioxidants, while a diet rich in dairy and animal fat products results in a higher risk 
of developing PD. Foods which cause high plasma urate may reduce PD risk because 
of urate’s ability to scavenge peroxynitrite and hydroxyl radicals resulting in 
decreased oxidative stress.  
Oxidative modification can cause mitochondrial decay, resulting in 
neurodegeneration. Supplementation with mitochondrial nutrients may prevent 
mitochondrial decay and the possible mechanisms may include: a. preventing 
mitochondria from oxidative stress, with nutrients such as lipoic acid, vitamin E and 
CoQ; b. repairing mitochondrial membranes, with nutrients such as carnitine; c. 
functionally repairing and preventing mitochondrial damage, such as substrates or 
coenzymes, or precursors of mitochondrial enzymes (quinine reductase and 
glutathione-S-transferase), with nutrients such as lipoic acid, niacin, pantothenic acid, 
riboflavinthiamine, biotin, and carnitine; d. inducing phase-2 enzymes to enhance 
antioxidant defenses in cytosol as an indirect protection to mitochondria, with 
nutrients such as lipoic acid.  
The combination of two mitochondrial nutrients may have more effective 
antioxidant capability than each has individually. It is reported that the combination of 
R-alpha-lipoic acid (LA) and acetyl-L-carnitine (ALC) has a synergistic action against 
rotenone-induced mitochondrial dysfunction, oxidative damage and a-synuclein 
accumulation at lower concentrations then they have individually (100-1000-fold 
lower).  
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Figure 2. Possible protective mechanisms of nutrients in mitochondria. B1, thiamine, B2, 
riboflavin; B3, niacin; B5, pantothenic acid; B6, pyridoxine; B12, cobalamin; CoQ, coenzyme 
Q10; Cyt C, cytochrome c, LA, alpha-lipoic acid; PDH, pyruvate dehydrogenase; alpha-KGDH, 
alpha-ketoglutarate dehydrogenase; BC-KADH, branched chain ketoacid dehydrogenase, CAT, 
carnitine acyltransferases; Carboxilase includes pyruvate carboxylase, acetyl-CoA carboxylase, 
and propionyl-CoA carboxylase, and THF-related enzymes includes methionine synthease, 
methylene tetrahydrofolate reductase.  
 
C. Green Tea Polyphenol Properties & Mechanisms of Protection 
Green tea catechines have been shown to have many biological actions, including 
antioxidant, free radical-scavenging, antiatherosclerotic, cardioprotective, 
anti-inflammatory, and anticarcinogenic effects. There is still controversy on the 
cancer-preventive, cardiovascular protective, or neuroprotective roles of green tea 
intake due to the limitation of data. Most of the results have come from studies using 
observational designs, case studies, case-control studies or cohort studies that lack the 
rigor of clinical trials. Detailed information on intake quantities and cumulative 
exposure to green tea (years of drinking) is lacking. However, human epidemiological 
studies suggest that tea consumption is inversely correlated with incidence of 
dementia, AD, and PD. In a cross-sectional study aimed at investigating an 
association between consumption of green tea and cognitive function in elderly 
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Japanese subjects, it was found that higher consumption of green tea is associated 
with lower prevalence of cognitive impairment (201). In a case-controlled study in the 
US, it was found that people that consumed 2 cups/day or more of tea presented a 
decreased risk of PD (202). In consensus, a recent prospective 13-year study of nearly 
30,000 Finnish adults, aged 25-74 years, demonstrated that drinking 3 or more cups of 
tea per day is associated with a reduced risk of PD (203). These findings emphasize 
the importance of well-designed controlled studies to assess a risk reduction of PD 
and AD in consumers of green tea. The beneficial effects of green tea are attributed to 
its polyphenolic compounds, particularly the catechins, approximately composing 
30% of the dry weight of green tea leaves. There are higher quantities of catechins in 
green tea than black or oolong tea due to the different processing steps. For green tea, 
the polyphenol oxidase enzymes are inactivated and maintained in the monomeric 
forms. Catechins account for 25–35% of the dry green tea extract and consist of eight 
polyphenolic flavonoid-type compounds, namely, (+)-catechin (C), (−)-epicatechin 
(EC), (+)-gallocatechin (GC), (−)-epigallocatechin (EGC), (+)-catechingallate (CG), 
(−)-epicatechin gallate (ECG), (+)-gallocatechin gallate (GCG) and EGCG. The most 
abundant catechin is EGCG, which accounts for 65% of the total catechin content in 
green tea. A cup of green tea (2.5 g of green tea leaves/200 ml of water) may contain 
90 mg of EGCG and thus is thought to particularly contribute to the beneficial effects 
attributed to green tea, such as its neuroprotective properties. Green tea and EGCG 
have been used in many different cells and animal models to investigate mechanisms 
underlying the various actions of green tea catechins.  
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Fig.3. Structures of the major polyphenolic catechins present in green tea. 
EGCG has been shown to improve age-related cognitive decline and protect against 
cerebral injuries and brain inflammation and neuronal damage in experimental 
autoimmune encephalomyelitis (204). Long-term administration of EGCG was 
demonstrated to improve spatial cognition learning ability in rats (206). In line with 
the in vivo findings, cell culture studies had demonstrated that EGCG prevented 
neuronal cell death caused by the neurotoxins 6-OHDA and MPP+ in several cell 
lines, such as human neuroblastoma SH-SY5Y cells and rat pheochromocytoma 
(PC12) cells. EGCG not only has cancer chemopreventive, anti-angiogenic and 
anti-mutagenic properties, but also has anti-diabetic properties in an insulin animal 
model and anti-bacterial, anti-HIV, anti-aging, and anti-inflammatory activity. EGCG 
has a catechol-like structure, which inhibits DA uptake, blocks DA competitors, 
exerting neuroprotective effects. EGCG also inhibits the activity of the enzyme 
COMT to block the metabolism of DA and related catecholamines. In addition, 
EGCG is able to regulate the proteolytic processing of a-synuclein and reassemble the 
structure of a-synuclein to convert it into a less toxic form. Beyond this, EGCG can 
also promote the non-amyloidogenic a-secretase pathways of APP to soluble APP, 
against AD. 
33 
Low concentrations of EGCG are responsible for the antiapoptotic/neuroprotective 
effects, whereas high doses account for its antiproliferative, antiangiogenic and 
pro-apoptotic actions (207). For example, low concentrations of EGCG decreased the 
expression of pro-apoptotic genes bax, bad, caspases1 and 6, cyclin-dependent kinase 
inhibitor p21, fas-ligand and tumor necrosis factor-related neuronal cells, while high 
concentrations induced apoptosis. Most of the effects of EGCG in cell culture systems 
have been observed with relatively higher concentrations than those in the plasma or 
tissues of animals or in human plasma after administration of green tea or EGCG. The 
reason may be that EGCG is subjected to form a dimer, and auto-oxidizes under cell 
culture conditions, reducing its half-life. It is not clear whether the activities observed 
with high concentrations of EGCG in cell lines can be observed in vivo. However, it is 
possible that increased consumption of green tea by humans could result in the 
buildup of higher concentrations of EGCG in the plasma.  
Bioavailability is an important factor for considering the beneficial effects of 
EGCG use in vivo. EGCG has only limited systemic availability. There have been 
some recent efforts to enhance its bioavailability by delivering EGCG using lipid 
nanocapsules and liposome encapsulation. Indeed, there has been successful in vitro 
and in vivo testing of the delivery of EGCG in polylactic acid-polyethylene glycol 
nanoparticles to inhibit angiogenesis and induce apoptosis. It is shown that nanolipid 
EGCG particles can significantly improve the neuronal α-secretase and have more 
than two-fold greater oral bioavailability than normal EGCG treatment on AD. Based 
on the current findings, additional large, long-term cohort studies and clinical trials 
should be performed to investigate the efficacy, pharmacology, safety, and 
side-effects of standardized preparations of green tea and EGCG.  
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1. EGCG Antioxidant Activity  
Exogenous antioxidants also play a major role in maintaining cellular redox 
balance. These include direct scavenging of HO·, singlet oxygen, etc. Tea catechins 
are powerful hydrogen-donating antioxidants and free radical scavengers of ROS and 
NOS in vitro. The anti-oxidant property of catechins is due to the presence of the 
phenolic hydroxyl groups on the B-ring in ungalloylated catechins (EC and EGC) and 
in the B- and D-rings of the galloylated catechins (ECG and EGCG) (208, 209). The 
presence of the 3, 4, 5-trihydroxy B-ring is important for antioxidant and 
radical-scavenging activity.  
The neuroprotective effect of green tea polyphenols in vivo may also involve the 
regulation of antioxidant protective enzymes through the Nrf2/ARE system. EGCG 
was found to elevate the activity of two major oxygen-radical species metabolizing 
enzymes, SOD and catalase, in mice striatum (206). In peripheral tissue it has been 
shown that EGCG at low concentrations activates the expression of some 
stress-response genes, such as phase II detoxification enzyme, 
glutathione-s-transferase and HO-1.  
 
2. EGCG & Iron Chelation  
The 3,4,5-trihydroxy B-ring of the catechins (shown in Fig. 3) have been shown to 
be important for antioxidant and radical scavenging activity. EGCG was shown to be 
more efficient as a radical scavenger due to the presence of the trihydroxyl group on 
the B- and D-rings and the gallate moiety at the 3’ position in the C ring. The green 
tea catechins have been shown to be more effective antioxidants than vitamin C and E, 
and the radical scavenging capability order is ECG>EGCG>EGC>EC>catechin. 
There are two points of attachment of transition metal ions to flavonoid molecules: 
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the o-diphenolic groups in the 3’,4’-dihydroxy positions in the B ring, and the keto 
structure 4-keto, 3-hydroxy or 4-keto and 5-hydroxy in the C ring of the flavonols. 
Therefore, the metal-chelating properties of green tea catechins are also important 
contributors to their antioxidative activity. The chelation capability of EGCG has 
major significance for the treatment of neurodegenerative diseases.  
Desferal/desferrioxamine (DFO) was shown to be neuroprotective against 6-OHDA 
and MPTP-induced neurotoxicity in rat and mouse models (212, 213). However, the 
hydrophilic nature and large molecular size of DFO limited its absorption across the 
gastrointestinal tract and prevents it from penetrating the BBB. EGCG has the 
capability to cross the BBB and possess relatively potent metal-chelating properties 
due to the gallate moiety present in the C-ring. EGCG and R-apomorphine prevented 
iron-dependent α-synuclein aggregation in the SN of MPTP-treated mice and restored 
the nigro-striatal DA neurons (214). The chelation of iron by EGCG also activates 
hypoxia signal transduction pathways, such as HIF-1, and regulates compensatory 
factors, including prolyl-4-hydroxylase, chaperones, and the immunoglobulin-heavy 
chain-binding protein, HSP90. EGCG can reduce the iron pool and activate IRP 
expression (215, 216). The regulation of IRP is coordinated with iron-related proteins, 
maintaining cellular iron hoemeostasis, survival, and proliferation, including ferritin, 
TfR and Fpn1, etc. 
 
Table 1. Iron chelators and neuroprotection 
Iron Chelators PD prevention 
Desferrioxamine Higher binding affinity to Fe
3+
 than Fe
2+
.  
Protects dopamine in rat PD model. Also inhibits iron-promoted radical 
damage in dopaminergic cell line in 6-OHDA. 
Unable to cross the BBB when orally administrated due to the particle size 
and hydrophilic feature. It has adverse effects. 
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Table 1. Iron chelators and neuroprotection (Continued)  
Clioquinol 
(5-chloro-7-iodo-8- 
hydroxyquinone) 
Reduces iron level in substantia nigra of mice.  
Pre-treatment prevents mice against MPTP toxicity.  
Produces unintended effects due to no iron selective, by reducing the S- 
adenosylmethionine level, resulting into vitamin B12 deficiency.  
Can be used orally.  
HLA20 Protects P19 cells (mouse embryonal carcinoma cell line) against 6-OHDA. 
Strong ferric chelator, can also inhibit MAO-B activity.  
VK-28 
(5-[4-(2-hydroxyeth
yl)piperazine-1-ylme
thyl]-quinoline-8-o1) 
Penetrates mitochondrial membrane.  
Protects dopaminergic neuron against 6-OHDA in rat. 
M30 
[5-(N-methyl-N-pro
pargyaminomethyl)- 
8-hydroxyquinoline 
Both iron chelator and MAO-B inhibitor. Similar to HLA20.  
More effective MAO-B inhibitor than HLA20 and VK-28 in vivo. 
Aroylhydrazones 
PCIH 
(2-pyridylcarboxald
ehyde isonicotinoyl 
hydrazone) 
Charged hydrazone can cross membrane and remove iron more effectively. 
H2O2-triggered 
prochelator  
SIH-B 
(2-borobenzalh 
dehyde isocotinoyl 
hydrazone) 
 
H2O2 can trigger for the transformation of prochelator SIH-B into the active 
chelator SIH, which in turn will form an inert complex with iron or copper 
and inhibit the Fenton reaction. Decrease the adverse effect of iron 
chelation. Experiment test in vivo is underway. 
 
Green tea 
polyphenols 
EGCG 
Inhibits cytochrome p450, GST, lipid peroixdation in vitro and in vivo 
studies. Strong antioxidant at lower concentration, while prooxidant at high 
concentration.  
Quercetin Inhibits Fenton reaction in vitro. Strong iron chelator in vivo. Protects 
mesencephalic dopamine neurons from apoptosis induced by MPP+.  
 
Curcumin Decreases the iron level in vitro against neurotoxin, even if not as 
effectively as DFO. Can protect dopamine level in 6-OHDA injected rat.  
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3. EGCG & Protein Kinase Signaling Pathways 
The neuroprotection of EGCG is shown to be involved in regulating intracellular 
signaling pathways, such as protein kinase C (PKC) in the SH-SY5Y cells (207, 217). 
To some extent, the PKC inhibitor can diminish the protection of EGCG. Therefore, 
interventions to modulate specific PKC activity or PKC mediated signal transduction 
pathways may constitute a potential therapeutic tool for neuroprotection. PKCε 
activation agonist was shown to be essential for neuroprotection against oxygen or 
glucose deprivation in vitro. EGCG has been shown to phosphorylate and activate 
PKC and protect against several neurotoxins, such as Aβ and 6-OHDA (207). EGCG 
can also relocate the isoform PKCα to the membrane compartment in PC12 cells. An 
animal study showed that two weeks of oral EGCG consumption prevented the 
depletion of PKCα and against Bax protein in the striatum and SN of mice with 
MPTP administration (218). In addition to PKC, other cell signaling pathways are 
implicated in the action of EGCG, such as the MAPK, phosphatidylinostitide 3’-OH 
kinase (PI3K)/Akt, and PKA signaling cascades and cell calcium influx regulation 
(219). In general, green tea catechin can activate MAPK in both neuronal and 
extraneuronal cultures to increase the extracellular signal-regulated kinase (ERK1/2) 
activity, which was suppressed by oxidative stress (220). Epicatechin was shown to 
stimulate phosphorylation of cAMP-response element binding protein (CREB) to 
regulate neuronal viability and synaptic plasticity activity via ERK1/2 and Akt in 
primary cortical neurons (221). Although EGCG had no effect on ERK1/2 
phosphorylative levels, it was able to counteract the decline in ERK1/2 induced by 
6-OHDA in neuroblastoma cells (207). 
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4. EGCG & Inflammation 
Since neuroinflammation reactions are closely related to PD, the inhibition of 
inflammation can be a preventive strategy for neurological disorders. EGCG is shown 
to be involved in the regulation of anti-inflammatory activity. The administration of 
EGCG reduced expression of IL1β, TNF, and TGF in C57BL/6 mice (222). EGCG 
can also indirectly regulate the inflammatory effect through down-regulation of 
NF-κB and up-regulation of PPARγ (223). Interestingly, it was found that higher dose 
of dietary supplement of EGCG can promote inflammation reaction in C57BL/6 mice, 
including TNF-a, IL-6, different from the protection effects of low dose (224). 
However, the mechanism by which EGCG regulates anti-inflammatory action is still 
unclear. Further studies are needed to clarify the involvement of EGCG in the 
inflammatory pathways.  
In summary, EGCG may prevent against PD progression by its antioxidant, 
anti-carcinogenic, and anti-inflammatory properties, and by regulating iron 
homeostasis. Further studies are required to clarify the mechanism in vivo. In addition, 
the treatment methods, concentration, and structure modification, which are all related 
to EGCG bioavailability, need to be investigated in animal models. Since limited data 
is available to show the protection of EGG in humans, newly designed human clinical 
trials are required to directly demonstrate the preventive effects of EGCG.  
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Abstract: Parkinson’s disease (PD) is a progressive neurodegenerative disease that 
causes severe DA depletion in the striatum of the brain and induces clinical signs such 
as tremor, rigidity, akinesia, immobility and frequent falls. Disruption of iron 
metabolism may be involved in the progression of PD. Our objective was to test 
whether the protective effect of (-)-epigallocatechin-3-gallate (EGCG) against 
6-hydroxydopamine (6-OHDA) induced neurotoxicity was by regulating iron 
homeostasis in N27 cells. The protection of EGCG was assessed by SYTOX Green 
assay, MTT and caspase-3 activity. Pretreatment of EGCG with 6-OHDA 
significantly increased (p<0.0001) TH
+
 cell count (~ 3-fold) and neurite length (~ 
12-fold) compared to 6-OHDA alone in primary mesencephalic neurons. 6-OHDA 
treatment significantly increased divalent metal transporter-1 (DMT1), hepcidin, and 
decreased ferroportin-1 (Fpn1) expression, while pretreatment of EGCG significantly 
altered these adverse effects of 6-OHDA. The increased ~2-fold (p<0.001) 
55
Fe cell 
uptake by 6-OHDA confirmed iron burden associated with neurotoxicity. 
Pretreatment of EGCG protected against the neurotoxicity by reducing the iron uptake 
and retention compared to 6-OHDA. In conclusion, pretreatment of EGCG (not 
co-treatment) protected against 6-OHDA induced neurotoxicity by regulating genes 
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and proteins involved in brain iron homeostasis. However, further studies are 
warranted to determine the mechanism of that regulation. 
 
Key words: EGCG, Iron, 6-OHDA, Parkinson’s disease 
 
Introduction 
Iron plays a crucial role in many physiological functions (1) including DNA 
synthesis, oxygen transport, and mitochondrial respiration (2, 3). Being a cofactor of 
tyrosine hydroxylase, iron is also involved in brain functions, such as 
neurotransmission and myelination (4, 5). It is important to regulate intracellular iron 
uptake, transport and storage. Iron homeostasis can be interrupted by dysfunction of 
iron related proteins, leading to the increased iron accumulation. The accumulation of 
unbound free iron in the cell further induces oxidative damage on cellular organelles 
by producing free radicals via the Fenton reaction (6), resulting in chronic 
neurological disorder diseases, including PD (7, 8).  
Iron homeostasis and metabolism are regulated by iron-related proteins. The 
divalent metal transporter 1 (DMT1) is one of the proteins responsible for intracellular 
iron uptake. DMT1 can be upregulated by neurotoxin, such as 6-hydroxydopamine 
(6-OHDA), resulting in intracellular iron accumulation, free radical formation and 
neurodegeneration (9-11). However, it is still unclear whether iron influx and 
subsequent free radical formation is a primary or secondary event in the 
neurodegenerative process. Hepcidin is a key iron regulatory protein that is 
responsible for normal iron homeostasis. Hepcidin is expressed in several organs, 
such as the liver, brain, spinal cord and is closely related to intracellular iron 
concentration. Its expression is also influenced by oxidative stress (12). Ferroportin 1 
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(Fpn1) is the iron exporter which exports intracellular iron. Hepcidin can bind to Fpn1, 
causing its internalization and degradation, promoting iron retention in the cell (13).  
It has been confirmed that 6-OHDA can induce oxidative stress and cause severe 
neuron cell death. 6-OHDA can release iron from ferritin (14, 15), induce depletion of 
PKC kinases, stimulate inflammatory factors and cause cell membrane potential 
hyperpolarization, etc. However, the detailed mechanisms remain unclear. Since 
6-OHDA is shown to alter DMT1 expression and oxidative stress (9), there is a 
possibility that 6-OHDA may exert its neurotoxicity by interrupting iron homeostasis 
and subsequent oxidative damage. 
Green tea polyphenol has been shown to provide beneficial effects against cancer, 
inflammation, neurological disorders, including PD. (-)-Epigallocatechin-3-Gallate 
(EGCG) is the most abundant polyphenol in green tea, and due to its capability of 
scavenging free radicals and chelating iron, it has been shown to protect against 
neurotoxins in several cell culture models of PD (16, 17). EGCG is reported to have 
antioxidant activity to reduce oxidative stress. It also can affect protein kinase and cell 
apoptosis. Several in vitro studies have shown EGCG reduces 6-OHDA neurotoxicity, 
but the mechanism of the protection is not clear. We hypothesized that 6-OHDA and 
EGCG administration would affect the regulation of iron via iron-related proteins. We 
used immortalized rat mesencephalic dopaminergic neuronal cell line (N27 cells) to 
determine whether 6-OHDA disrupted iron metabolism by regulating iron transporters, 
such as DMT1, Fpn1 and hepcidin, etc. We also determined whether EGCG protected 
against the adverse effects of 6-OHDA by normalizing and maintaining iron 
homeostasis.  
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Materials and Methods 
Reagents. EGCG, 6-OHDA, and thiazolyl blue tetrazolium bromide (MTT) were 
purchased from Sigma–Aldrich (St. Louis, MO). SYTOX® Green Nucleic Acid Stain 
was from Molecular Probes (Eugene, OR). Substrate for caspase-3, 
Acetyl-Asp-Glu-Val-Asp-AFC (Ac-DEVD-AFC), was obtained from MP 
Biomedicals (Solon, OH). The mouse TH
+
 antibody was obtained from Millipore 
(Temecula, CA); Alexa 680-conjugated anti-mouse secondary antibodies, RPMI-1640 
medium, fetal bovine serum, l-glutamine, penicillin, streptomycin and neurobasal 
medium, B27 supplement, and Dulbecco’s modified Eagle’s medium (DMEM) were 
obtained from Invitrogen (Carlsbad, CA). Rabbit anti-rat-DMT1 polyclonal antibody, 
rabbit anti-rat-MTP1 polyclonal antibody and rabbit anti-rat-hepcidin polyclonal 
antibody were purchased from Alpha Diagnostic International (San Antonio, TX), 
β-actin mouse-anti-mouse-monoclonal antibody was from were from Sigma 
Chemicals (St. Louis, MO). Secondary antibody Goat-anti-rabbit-IgG-HRP and 
Goat-anti-mouse-IgG-HRP were obtained from Santa Cruz Biotechnology (Dallas, 
TX). Supersignal west femoto chemiluminescent substrate for western blotting was 
from Thermo Scientific (Rockford, IL). 
55
Fe was purchased from Perkinelmer 
(Waltham, MA).  
Cell culture. N27 cells were grown in RPMI-1640 medium containing 10% fetal 
bovine serum, 2 mmol/L l-glutamine, 50 U penicillin and 50 μg/mL streptomycin and 
maintained at 37
◦
C in a humidified atmosphere containing 5% CO2 as described in 
previous studies (18). We also used primary mesencephalic neuronal cultures to 
determine the neuroprotective effect of EGCG. Primary mesencephalic neuronal 
cultures were prepared from the ventral mesencephalon of gestational 14-day-old C57 
black mice embryos as described previously (19). Mesencephalic tissues were 
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dissected and kept in ice-cold Ca
2+
-free Hanks’ balanced salt solution. Cells then were 
dissociated in Hans’ balanced salt solution containing trypsin, 0.25% EDTA for 30 
min at 37
◦
C. Cells were suspended in neurobasal medium with 2% neurobasal 
supplement (B27) after 10% FBS inactivating enzyme activity in DMEM medium. 
The cells were then plated at density of 0.5 × 10
6
 cells on 12-mm coverslips precoated 
with 1 mg/ml poly-D-lysine. Cell cultures were maintained in 500 μM l-glutamine, 
100 IU/ ml penicillin, and 100 units streptomycin neurobasal medium, incubated in a 
humidified CO2 incubator (5% CO2 and 37
◦
C). Medium was replaced half every 2 
days and assays were conducted using cultures at 7 days old. Primary mesencephalic 
dopaminergic neuronal cells were exposed to 6-OHDA (25 μM) for 24 h in the 
presence or absence of 2 h pretreatment of EGCG (1, 10 and 100 μM). Cells were 
then fixed for immunocytochemical analysis. 
Sytox green assay. Equal numbers of N27 cells grown in 24-well plates with 500 
μl RPMI medium co-incubated with 1:1000 Sytox green dye. To determine the effects 
of 6-OHDA and EGCG and protective effect of dosage from EGCG, N27 cells were 
pretreated with EGCG at concentrations of 1, 10, 50 and 100 μM for 2 h, and then 
followed by 6-OHDA (100 μM) treatment for 6 h. The assessment of cell death was 
conducted using Sytox green nucleic stain as described previously (19). After each 
treatment, Sytox green signal was detected using a fluorescence microplate reader 
(Bio-Tek microplate reader) at an excitation wavelength of 485 nm and an emission 
wavelength of 538 nm. The intensity of fluorescence was directly proportional to the 
number of dead cells. To quantify cell death, fluorescence intensity was monitored 
after the experiments were conducted and fluorescence pictures were taken using a 
Nikon inverted fluorescence microscope equipped with a SPOT digital camera 
(Diagnostic Instruments, Sterling Heights, MI). 
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Cell viability. The N27 cells were pretreated and cotreated with EGCG (100 μM), 
followed by 6-OHDA treatment for 6 h, the cell viability was measured by MTT 
assay as described previously (20). Briefly, after treatments, cells were washed with 
PBS and then incubated with serum free RPMI medium containing 0.25 mg/mL MTT 
reagent for 3 h at 37
◦
C. Isopropanol–HCl (300 μl) solution was added to dissolve 
intracellular purple formazan and absorbance was read at 570 nm with a reference 
wavelength of 630 nm using a microplate reader (Molecular Devices, Sunnyvale, 
CA).  
Caspase-3 activity. Caspase-3 activity was measured to assess cell apoptosis as 
previously described (21). Briefly, N27 cells was pretreated with EGCG for 2 h, 
followed by 6-OHDA treatment for 6 h, then the cells were resuspended in lysis 
buffer (50 mM Tris-HCl, 1 mM EDTA, and 10 mM EGTA) containing 10 mM 
digitonin for 20 min at 37°C. Supernatants were treated with the fluorogenic 
substrates Ac-DEVD-AFC for 1 h at 37°C and fluorescence was measured at 
excitation at 400 nm and emission at 505 nm using a Gemini XS fluorescence plate 
reader (Molecular Devices Inc). The activity was measured as fluorescent units 
(FU)/mg protein. 
Immunocytochemistry. After treatments, the primary cultures were processed for 
immunocytochemical analysis. Briefly, the cells were fixed with 4% 
paraformaldehyde and permeabilized, and nonspecific sites were blocked with 5% 
normal goat serum containing 0.4% BSA and 0.2% Triton-X 100 in PBS for 20 min. 
Cells were then incubated with antibodies directed against TH (1:500) overnight at 
4°C followed by incubation with Cy3-conjugated (1:1000) secondary antibody for 1 h 
at room temperature. Secondary antibody treatments were followed by incubation 
with 10 μg/ml Hoechst 33342 for 3 min at room temperature to stain the nucleus. 
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Then the coverslips containing cells were washed with PBS, mounted on a slide, and 
viewed under a Nikon inverted fluorescence microscope (Model TE-2000U) and 
images were captured with a SPOT digital camera (Diagnostic Instruments, Sterling 
Heights, MI). TH
+
 cell count and neurite processes were measured as described (18). 
Briefly, the total number of TH
+
 cells averaged 14/coverslip in untreated 
mesencephalic cultures. For measurement of TH
+
 cell count, Metamorph Image 
analysis software was used. The images were first thresholded, and then neuronal 
count and volume were measured using the Integrated Morphometry Analysis (IMA) 
function. For measurement of neuronal processes, the lengths of the processes were 
marked by applying the region and length measurement function in the IMA.  
Quantitative real-time PCR analyses. The mRNA expression levels of DMT1, 
Fpn1, hepcidin, transferring receptor (TfR) and H-ferritin were quantified using 
real-time PCR as described previously (22, 23). Briefly, N27 cells were pretreated 
with EGCG and followed by 6-OHDA for 24 h. Total RNA was isolated from the 
cells using absolutely RNA miniprep kit (Stratagene, Santa Clara, CA) and reverse 
transcripted by High Capacity cDNA Reverse Transcription Kits (Applied Biosystems, 
Foster City, CA). Quantitative real-time RT-PCR was performed using Brilliant 
SYBR Green QPCR Master Mix kit and the Mx3000P QPCR system (Stratagene, 
Santa Clara, CA). The 25 μl PCR reaction mixture included 1 μl of cDNA (produced 
by 100 ng of RNA), 12.5 μl of 2 × master mix, and 100 nM each primer (listed in 
Table 1). Cycling conditions contained an initial denaturation at 95°C for 10 min, 
followed by 40 cycles of amplification 95°C for 30 s for denaturation, 60°C for 30 s 
for annealing, and 72°C for 30 s for extension. Fluorescence was detected during the 
annealing/extension step of each cycle. Dissociation curves were used to verify the 
specificity of the PCR products. GAPDH gene was used as internal control. A 
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comparative threshold cycle method was used to analyze the data. All reactions were 
performed in triplicate. 
Western blot analyses. DMT1, hepcidin and Fpn1 expression were evaluated by 
Western blot assay. N27 cells were pretreated with EGCG and followed by 6-OHDA 
for 24 h. Then the cells were washed with cold PBS and homogenized in RIPA buffer 
containing 1% Triton X-100, 0.1% SDS, 1 mM phenylmethanesulfonyl fluoride 
(PMSF) and protease inhibitors (pepstatin 1 mg/ml, aprotinin 1 mg/ml, leupeptin 1 
mg/ml), and then sonicated on ice. After a centrifugation at 13,000 rpm for 15 min at 
4°C, the supernatant was collected. Aliquots of supernatants were assayed for protein 
concentrations. Forty μg of protein extract was mixed with an equal volume of 5 × 
sample buffer (0.35 M Tris–HCl, 10% SDS, 30% glycerol, 0.012% bromophenol 
blue), and loaded onto a 12 % or 15 % SDS-polyacrylamide gel or Urine-gel, 
electrophoresed, and then transferred to a nitrocellulose membrane (Bio-Rad, 
Hercules, CA). The membrane was blocked with 5% nonfat dry milk in TBST and 
then incubated with rabbit anti-rat DMT1 with IRE polyclonal antibody (1:200), 
rabbit anti-rat Fpn1 polyclonal antibody (1:500) or rabbit anti-rat hepcidin polyclonal 
antibody (1:500), followed by horseradish peroxidase-conjugated goat anti-rat IgG 
antibodies (1:3000). To ensure even loading of the protein samples, β-actin (1:2000) 
was used as internal control, with the incubation of the corresponding 
goat-anti-mouse-IgG-HRP secondary antibody (1:3000). All western blot assays were 
performed triplicately in two separate experiments. 
Cellular iron uptake. N27 cells were grown in 12-well plates. After 2 h 
pretreatment with EGCG, N27 cells were exposed to 6-OHDA, and ferric chloride 
(0.5 μCi/ml 55Fe) was also added to the media and incubated at 37°C for 24 h. Cell 
were then washed in cold 1 × PBS twice and lysed in 250 μl of lysis buffer (RIPA 
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buffer). After centrifuging at 13,000 rpm for 10 min at 4°C, 50 μl of supernatant was 
used to measure the 
55
Fe radioactivity in a scintillation counter mixed with the 10 ml 
cocktail scintillation fluid. The 
55
Fe uptake was calculated by dividing the number of 
counts per minute (CPM) and the values were normalized to cell protein concentration. 
The experiments were performed in duplicate.  
Statistics analyses.  Data were analyzed with Prism 4.0 software (Graph Software, 
San Diego, CA). All values are expressed as mean ± SEM and represented as 
percentage of the respective controls. ANOVA with Tukey’s multiple comparison test 
was used to detect the differences among treatments. Student t-test was used to 
compare the difference between 6-OHDA with EGCG pretreatment and 6-OHDA 
alone groups in iron related genes expression. The mean differences were considered 
significant at p<0.05. 
 
Results 
Effects of 6-OHDA and EGCG on cell death 
The Sytox green assay showed the dose response of EGCG protected against 
6-OHDA induced cell death (Fig. 1). 6-OHDA significantly increased cell death by 
196% (p<0.0001) compared to control. Pretreatment of EGCG at a concentration of 
50 and 100 μM for 2 h decreased the cell death by 31 % (p<0.0001) and 55% 
(p<0.0001) compared to 6-OHDA alone group. There was no significant decrease in 
EGCG pretreatment at the concentration of 1 and 10 μM.  
EGCG protected against 6-OHDA induced decreased cell viability  
As showed in Fig 2., cell viability was decreased to 59% (p<0.001) after 6 h 
treatment with 6-OHDA, but EGCG pretreatment for 2 h partially protected against 
this toxicity significantly by 21% (p<0.01). In contrast, only 10% (p>0.05) increase in 
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cell viability in EGCG co-treatment group, suggesting pretreatment of EGCG shows 
the protective effect. 
EGCG protected against 6-OHDA induced cell apoptosis 
Caspase-3 activity was used to determine the cell apoptosis (Fig. 4). Compared to 
control, 6-OHDA significantly increased caspase-3 activity by ~ 12-fold (p<0.0001), 
while pretreatment of EGCG for 2 h decreased the caspase-3 activity by 49% 
(p<0.0001) compared to 6-OHDA. There was no change in caspase-3 activity in 
EGCG treatment alone group, suggesting EGCG pretreatment protected against cell 
apoptosis.  
EGCG decreased TH
+
 neuronal loss from 6-OHDA in primary mesencephalic 
cultures 
Treatment with 6-OHDA for 24 h induced ~ 80% (p<0.0001) loss of TH
+
 cell count 
(Fig. 5A), compared to control. Pretreatment of EGCG (1, 10, 100 μM) for 2 h 
significantly increased TH
+
 cell count by 155% (p<0.01), 205% (p<0.0001) and 290% 
(p<0.0001), respectively (Fig. 5B). The average lengths of TH
+
 neuronal processes in 
EGCG pretreated cells were significantly longer than the processes of neurons with 
only 6-OHDA treated. We also found that 6-OHDA significantly decreased the TH
+
 
neurite length by 93% (p<0.0001), while pretreated with EGCG (1, 10, 100 μM) for 2 
h significantly increased the neurite length by ~ 10-fold (p<0.0001), 12-fold 
(p<0.0001), and 12-fold (p<0.0001), respectively (Fig. 5C). In addition, 6-OHDA 
significantly decreased Hoechst activity, while pretreatment of EGCG (1, 10, or 100 
μM) increased Hoechst staining (Data not shown), suggesting the increased cell 
availability. Overall, EGCG protected against 6-OHDA toxicity in primary cultures. 
EGCG altered the 6-OHDA regulation on the mRNA expression of iron-related genes 
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As shown in the Table 2, 6-OHDA significantly increased the mRNA expressions 
of DMT1+IRE, hepcidin, TfR2, H-ferritin and decreased Fpn1 and TfR1. However, 
EGCG altered the effects by decreasing DMT1+IRE by 60% (p<0.001), hepcidin by 
54%, (p<0.05), H-ferritin by 53%, (p<0.05), TfR2 by 27%, (p<0.05), while increasing 
Fpn1 by 70%, (p<0.01) and TfR1 by 96%, (p<0.01), compared to 6-OHDA, may 
indicate the reduced iron burden in the cell.  
EGCG altered the 6-OHDA regulation on the iron-related protein expressions 
The regulation on iron related proteins DMT1+IRE, hepcidin and Fpn1 was 
assessed by western blot. We found that 6-OHDA significantly increased DMT1+IRE 
expression by 201% (p<0.05), hepcidin by 177% (p<0.05) and decreased Fpn1 by 
61% (p<0.0001) compared to the control. Pretreatment of EGCG altered these effects 
by decreasing DMT1+IRE by 66% (p<0.01), hepcidin by 43% (p<0.05) and 
increasing Fpn1 by 82% (p<0.01) compared to 6-OHDA alone.  
EGCG reduced iron burden induced by 6-OHDA 
As shown in Fig. 7, 6-OHDA significantly increased 
55
Fe uptake to 196% (p<0.01). 
Pretreatment of EGCG significantly decreased 
55
Fe in the cell by 27% (p<0.05) 
compared to 6-OHDA, supporting the results of and mRNA and protein expression. 
 
Discussion 
Neurotoxins, such as 6-OHDA, have been widely used to establish PD model both 
in vitro and in vivo studies (9, 24, 25). Due to the abilities to induce oxidative stress, 
mitochondrial dysfunction and iron dyshomeostasis, 6-OHDA has been reported to 
cause significant neuronal cell death, including SH-SY5Y, PC12. High dose of 
6-OHDA treatment causes severe insult to cells and is effectively used for short-term 
and acute pathological research. It was shown that the treatment of 6-OHDA at 100 
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μM for 6 h caused a complete loss of cell viabilities (26). In our study, we also found 
that 6-OHDA at the same condition significantly increased dopaminergic N27 cell 
death approximately 3-fold, cell apoptosis ~ 12-fold and decreased cell viability by 
~40%. Relative lower concentration of 6-OHDA induced a smaller, but significant 
decrease in cell viability and increase in apoptosis, which benefits the clarification of 
mechanism of toxin induced neurodegeneration (27). In our study, we used a lower 
dose of 6-OHDA (25 μM) to determine the regulation on iron-related mRNA and 
protein expression, as well as the intracellular iron uptake. Although higher amounts 
of 6-OHDA (200 μM) has been reported to induced rat primary nigral culture death 
(28), lower concentrations (<50 μM) are used by most primary neuron studies due to 
sensitivity of neuron (29, 30). In our study, we used 10 μM 6-OHDA to show the 
significant TH+ cell loss after 24 h. Overall, the dose of 6-OHDA used in the study 
depends on the cell types and the study aims.  
Although the mechanisms of 6-OHDA induced neurotoxicity remain unclear, 
several pathways have already been proposed, such as mitochondrial dysfunction, 
inflammation, etc. It has been reported that 6-OHDA is able to release iron from 
ferritin and alter DMT1 expression, suggesting that 6-OHDA might exert its toxicity 
by interrupting iron homeostasis (31, 32). We found the disruption of iron metabolism 
was closely related to the alteration of iron transporters and iron regulatory proteins. 
In our study, we showed 6-OHDA up-regulated DMT1+IRE, hepcidin and decreased 
Fpn1 expression, which might result in an excess iron condition. The alteration on 
other iron-related factors, such as ferritin, TfR1, TfR2 by 6-OHDA also indicated an 
intracellular iron excess status. Our 
55
Fe uptake data further confirmed 6-OHDA 
caused high intracellular iron (~ 2-fold, p<0.01).  
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It was shown that the up-regulation of DMT1 by 6-OHDA occurred in an 
IRE/IRP-dependent manner (33, 34), indicating 6-OHDA may affect the activity of 
IRPs, altering the translation and stabilization of DMT1 mRNA. In our study, 
6-OHDA did not alter the expression of DMT1 without IRE (data not shown), also 
suggesting the regulation on DMT1 via IRPs. The increase of DMT1 caused iron 
influx, leading to oxidative stress. However, further studies are required to clarify 
whether there is causal-effect relationship between DMT1 and oxidative stress. 
Hepcidin is mainly involved in regulating iron homeostasis and can be regulated by 
iron influx and iron overloading (35, 36), oxidative stress and inflammation. In our 
study, we showed 6-OHDA significantly increased hepcidin expression in N27 cells. 
The regulation on hepcidin may depend on the excess intracellular iron, which was 
supported by the increased ferritin and 
55
Fe uptake. It was shown that TfR2 was 
positively associated with hepcidin expression and may be another hepdicin regulator 
(37, 38). Our data confirmed that increased TfR2 expression was accompanied by 
increased hepcidin level. Since hepcidin can bind to Fpn1 and induce its 
internalization and degradation, the increased hepcidin suppressed Fpn1 expression, 
resulting in iron retention. 6-OHDA can cause not only the decreased Fpn1 shown in 
our study, but also in primary mesencephalic neuron, MES23.5 cell (39, 40). The iron 
overloading can also decrease Fpn1 in PC12 (41). Other studies showed toxin can 
increase Fpn1 in primary cultured astrocytes, SH-SY5Y (40, 42). The difference of 
Fpn1 regulation may imply the significance of different cell type in neuronal iron 
homeostasis.  
Since the alteration of iron level in the brain is linked to several neurological 
disorders, maintaining normal iron homeostasis seems to be an ideal strategy for 
neuroprotection (43). As iron chelator and antioxidant, EGCG has been reported to 
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protect against neurotoxicity in numerous studies (44-46). In this study, we found that 
EGCG protected N27 cell against 6-OHDA induced cell death. The EGCG 
pretreatment method was considered more effective than co-treatment. We also found 
that EGCG (10-100 μM) exerted protection both in N27 cell and primary cultures and 
the concentration at 100 μM showed the best protective effects, whereas higher dose 
(> 200 μM) was found to be toxic (supplement data). This finding matched the 
bell-shaped pattern of EGCG as a typical of antioxidants, showing neuroprotection at 
low concentrations, and being pro-oxidant at high concentration (16, 17). We also 
confirmed that EGCG (1 μM -100 μM) protected TH+ cells against 6-OHDA toxicity 
in primary cultures. Different dosages of EGCG were also reported in other primary 
cultures studies. It showed lower dose (<10 μM) of EGCG protected neurons against 
6-OHDA (47, 48), while other studies reported higher (25 to 400 μM) EGCG 
protected SH-SY5Y cell apoptosis induced by 6-OHDA (24).  
Several proposed mechanisms may attribute to the neuroprotection of EGCG. First, 
it may regulate the iron-related proteins, maintain normal iron homeostasis (49). In 
this study, we showed the pretreatment of EGCG counteracted the adverse effect on 
iron-related proteins by 6-OHDA, leading to less intracellular iron accumulation. The 
decreased iron accumulation by EGCG pretreatment was supported by our 
55
Fe 
uptake data, showing 27% (p<0.05) decrease in iron burden against 6-OHDA. Second, 
EGCG may chelate the iron and the complex form of iron cannot be used by the cell, 
reducing the iron induced ROS generation. We have shown the decreased 
55
Fe uptake 
and decreased ROS in another study (data not shown). Third, EGCG may also 
enhance the antioxidant system by up-regulating antioxidant enzyme (16, 50), and 
scavenging the free radicals directly. The decreased oxidative stress may also affect 
the iron homeostasis directly or indirectly. In this way, EGCG causes less iron and 
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maintains the iron homeostasis. In addition, since the inflammation is related to 
antioxidation and EGCG was shown to reduce inflammatory activity, it may indirectly 
affect antioxidation and iron related protein. Further studies are needed to investigate 
how EGCG regulates iron metabolism in neural cells.  
In summary, 6-OHDA induced neurodegeneration may be via affecting iron 
metabolism. The increased DMT1 expression significantly caused iron influx into cell 
body, while decreased Fpn1 expression might have exacerbated iron accumulation. 
The increased hepcidin, ferritin and 
55
Fe suggest the increased free iron concentration, 
resulting into oxidative stress. EGCG exerted the protective effects against 6-OHDA 
by decreasing DMT1, hepcidin, increasing Fpn1 and reducing cell iron uptake to 
maintain normal iron level. EGCG may protect against neurotoxicity by modulating 
iron homeostasis. Further studies are needed to elucidate the mechanisms of 
protection by EGCG in vivo.  
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FIGURE 1 Effects of 6-OHDA and EGCG on cell death. The value are expressed as 
mean ± SEM, n=8. Labeled means without a common letter differ, * P<0.001. 
6-OHDA, 100 μM.   
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FIGURE 2 Effects of 6-OHDA and EGCG on cell viability. Cell viability was 
evaluated by MTT assay and the values are expressed as mean ± SEM, n=6. Data are 
represented as % of control (no treatment). Labeled means without a common letter 
differ. 6-OHDA, 100 μM for 6 h; EGCG 100 μM. Pre-trt, EGCG pretreatment 2 h, 
Co-trt, EGCG cotreatment with 6-OHDA. *P<0.01. **P<0.001  
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FIGURE 3 Effects of 6-OHDA and EGCG on cell apoptosis. Cell apoptosis was 
measured as caspase-3 activity. The values are expressed as mean ± SEM, n=3. 
Labeled means without a common letter differ. 6-OHDA, 100 μM for 6 h; EGCG 100 
μM. *P<0.001.  
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FIGURE 4 EGCG prevented TH
+
 neuronal loss by 6-OHDA. Immunochemistry 
analysis was processed and measured with TH
+
 cell count (Green color) and neurite 
length. Hoechst nuclear staining (Blue color) was used to identify the live cells (A). 
Quantification data on TH+ number (B) and neurite length (C). The values are 
expressed as mean ± SEM, n=3. Labeled means without a common letter differ. 
6-OHDA, 10 μM for 24 h; EGCG 1, 10, 100 μM pretreatment 2 h. *P<0.01, *P<0.001. 
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FIGURE 5 Effect of 6-OHDA and EGCG on iron-related proteins expression. 
Western blot analysis on (A) DMT1 (+IRE), (B) Hepcidin, (C) Fpn1 proteins 
expression which were normalized by β-actin in N27 cells. Quantificative data are 
shown in the bottom panels D, E, F, respectively. The values are expressed as mean ± 
SEM, n=3. Labeled means without a common letter differ. 6-OHDA, 25 μM for 24 h; 
EGCG 100 μM pretreatment 2 h. *P<0.01, *P<0.001. 
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FIGURE 6 Iron uptake were the amount of 
55
Fe taken by the cell, which was 
calculated by count per minute (CPM) normalized with protein concentration. The 
values are expressed as mean ± SEM, n=3. Labeled means without a common letter 
differ. 6-OHDA, 25 μM for 24 h; EGCG 100 μM. *P<0.05, **P<0.01. 
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TABLE 1 Summary of the primers for iron-related gene expression 
Hep Forward GAA GGC AAG ATG GCA CTA AGC A 
Hep Reverse TCT CGT CTG TTG CCG GAG ATA G 
Fp1 Forward CCA CCT GTG CCT CCC AGA T 
Fp1 Reverse CCC ATG CCA GCC AAA AAT AC 
DMT1+IRE Forward CAG TGC TCT GTA CGT AAC CTG TAA GC 
DMT1+IRE Reverse CGC AGA AGA ACG AGG ACC AA 
H-fer Forward GCC CTG AAG AAC TTT GCC AAA T 
H-fer Reverse TGC AGG AAG ATT CGT CCA CCT 
TfR1 Forward CTA GTA TCT TGA GGT GGG AGG AAG AG 
TfR1 Reverse GAG AAT CCC AGT GAG GGT CAG A 
TFR2 Forward AGC TGG GAC GGA GGT GAC TT 
TFR2 Reverse TCC AGG CTC ACA TAC ACG ACA G 
GAPDH Forward CCT GGA GAA ACC TGC CAA GTA T 
GAPDH Reverse AGC CCA GGA TGC CCT TTA GT 
All the primers were synthesized from Integrated DNA Technologies. 
 
 
 
 
 
 
 
 
 
 
85 
TABLE 2 Effect of 6-OHDA and EGCG on the iron-related genes expression  
              Mean  
 6-OHDA EGCG+6-OHDA  * 
DMT1+IRE 2.3±0.2* 0.9±0.0
ns
 <0.001 
Hepcidin 1.7±0.1* 0.8±0.2
ns
 <0.01 
Fpn1 0.7±0.0* 1.2±0.2
ns
 <0.05 
H-ferritin 2.4±0.4* 1.1±0.2
ns
 <0.05 
TfR1 0.7±0.0* 1.3±0.1
ns
 <0.01 
TfR2 1.5±0.1* 1.1±0.1
ns
 <0.05 
Data were presented as mean ± SEM, n=3-6. Values represent the fold changes of the 
ratio of mRNAs/GAPDH in treatments compared with control. Symbol * indicated 
difference between 6-OHDA group and EGCG pretreatment group, and was 
determined using student t-test. * p<0.05; ns, no significance. 
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Abstract 
6-hydroxydopamine (6-OHDA) is classic neurotoxin being used for Parkinson’s 
disease research. 6-OHDA can increase intracellular reactive oxygen species (ROS) 
and cause cell damage, which can be attenuated by (-)-Epigallocatechin-3-gallate 
(EGCG) treatment. However, the mechanism by which EGCG protects against 
6-OHDA toxicity remains unclear. In this study, we used CM-H2DCFDA probe to 
determine the ROS level in N27 cells. A significant increase in ROS generation after 
6-OHDA (25 μM) treatment was found, while EGCG (100 μM) attenuated the ROS 
generation. We evaluated the oxidative damage by determining thobartituric acid 
reactive substances (TBARS) and protein carbonyl content. 6-OHDA significantly 
increased TBARS by 82.7% (p<0.05) and protein carbonyl content by 47.8 (p<0.05), 
compared to the control. Pretreatment of EGCG decreased lipid peroxidation and 
protein carbonyls by 36.4% (p<0.001) and 27.7% (p<0.05), respectively, compared to 
6-OHDA. We also used western blot to test the E2-related factor 2 (Nrf2), heme 
oxygenase-1(HO-1) and peroxisome-proliferator activator receptor γ (PPARγ) 
expression to evaluate the antioxidant and antiinflammation. 6-OHDA increased Nrf2 
expression by 69.6% (p<0.001), HO-1 by 173.3% (p<0.001) and PPARγ by 122.7% 
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(p<0.001), compared to the control. Pretreatment of EGCG significantly normalized 
these alterations induced by 6-OHDA. In conclusion, our results suggested that the 
neurotoxicity of 6-OHDA in N27 cells was associated with ROS and inflammation 
pathways, whereas pretreatment of EGCG suppressed the ROS generation, resulting 
into the inactivation of Nrf2/HO-1 and PPARγ pathway.  
 
Introduction 
6-hydroxydopamine (6-OHDA) can induce neurological damage, which is similar 
to Parkinson’s disease (PD). One of the main features of the neurotoxicity of 
6-OHDA is involving in reactive oxygen species (ROS) generation. An increase in 
intracellular ROS production would disrupt redox homeostasis, cause oxidative stress 
and result into the irreversible oxidative modification on DNA, lipids and proteins (1). 
The presence of excess intracellular Fe (II) and Fe (III) may promote the generation of 
hydroperoxyl radical (HO·) through the Fenton reaction. Our previous in vitro study 
showed 6-OHDA induced the intracellular iron burden in immortalized rat 
mesencephalic dopaminergic neuronal cell line (N27) cells. Therefore, the excess iron 
may be involved in ROS generation and PD progression.  
The transcription factor nuclear factor E2-related factor 2 (Nrf2) and antioxidant 
response element (ARE) (Nrf2/ARE system) in cells can scavenge ROS and maintain 
the redox homeostasis. Nrf2 is the main factor to activate antioxidant enzymes, phase 
II detoxification enzymes (2, 3), such as heme oxygenase-1(HO-1). The activation of 
detoxification enzymes directly scavenge free radicals and decrease the toxicity (4). 
There are several ways to trigger Nrf2/ARE system to increase antioxidant enzyme 
activity. For example, oxidative stress and electrophiles are the major activators on 
Nrf2. 6-OHDA has been shown to induce Nrf2 expression due to the induced 
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oxidative stress. In addition, the activation of Nrf2 can also be positively managed by 
itself (5).  
Inflammation has a major impact on toxin-induced pathogenesis for PD (6, 7). The 
increasing evidence showed the positive correlationship between dopaminergic 
neurodegeneration and neuroinflammation (8). It has been shown that microglia 
inflammation was activated in 6-OHDA treated rats, indicating the critical role of 
inflammation in PD progression (9). The intracellular anti-inflammatory system, such 
as the peroxisome-proliferator activator receptors (PPAR), is responsible for 
suppressing inflammation reaction and maintaining normal redox status. One of the 
isoforms, PPARγ has the anti-inflammatory abilities and its agonists can used to treat 
inflammation-related diseases, including PD (10). In addition, PPARγ can also 
interact with Nrf2/ARE antioxidant system (11-16). It has been reported that PPARγ 
is involved in regulating HO-1 expression (17, 18). The relationship between Nrf2 
and PPARγ suggests that oxidative stress and inflammation are interacted. Nrf2 can 
regulate PPARγ expression under oxidative stress, thereby affecting 
anti-inflammatory activity (14, 19). Therefore, antioxidation and anti-inflammatory 
pathways might be simultaneously involved in neurodegeneration. However, detailed 
mechanisms of the interaction between Nrf2 and PPARγ are not clear at this time.  
Since iron burden and ROS are attributed to neuronal damage, iron chelation and 
antioxidative strategies are useful to protect neurodegeneration. 
(-)-Epigallocatechin-3-gallate (EGCG) is an antioxidant used to counteract neurotoxin 
and oxidative damage due to its iron chelation and free radical scavenging capabilities. 
EGCG can induce the expression of several antioxidant enzymes, and eliminate ROS 
and electrophile generation in the progression of neurodegeneration. EGCG has also 
been shown to inhibit the inflammatory reactions against cancer and neurological 
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diseases (20). It has been shown that EGCG treatment can prevent against 
environmental toxin, such as 6-OHDA induced neurodegeneration both in vitro and in 
vivo. However, the mechanism by which EGCG exerts its neuroprotection remains 
unclear. In this study, we hypothesized that 6-OHDA increased ROS levels and 
inflammation reaction, and cause oxidative damage in N27 cells, and EGCG 
treatment may prevent the adverse effects by stabilizing the Nrf2, PPARγ system, and 
thus reducing the oxidative damage on lipids and proteins.   
 
Materials and Methods 
Reagents. EGCG, 6-OHDA, Hanks’ Balanced Salts (HBSS) used for cell culture 
were purchased from Sigma (St. Louis, MO). RPMI-1640 medium, fetal bovine 
serum, L-glutamine, penicillin, streptomycin and CM-H2DCFDA oxidative indicator 
probe were obtained from Invitrogen (Carlsbad, CA). Trichloroacetic Acid (TCA) 
was purchased from Fisher Scientific (Pittsburgh, PA). 1, 1, 3, 3-tetramethoxypropane, 
2-Thiobarbituric Acid (TBA) were purchased from Sigma (St. Louis, MO). Protein 
carbonyl was assessed by commercial kit from Cayman Chemical Company (Ann 
Arbor, MI). Protein concentration was determined by Pierce BCA protein assay kit 
(Rockford, IL). Rabbit anti-rat-Nrf2 polyclonal antibody, rabbit anti-rat-HO-1 
polyclonal antibody and rabbit anti-rat-PPARγ antibody, secondary antibody 
goat-anti-rabbit-IgG-HRP and goat-anti-mouse-IgG-HRP were purchased from Santa 
Cruz Biotechnology (Santa Cruz, CA). β–actin mouse-anti-mouse-monoclonal 
antibody was purchased from Sigma (St. Louis, MO). 
Cell culture. N27 cells were grown in RPMI-1640 medium containing 10% fetal 
bovine serum, 2 mmol/L l-glutamine, 50 U penicillin and 50 μg/mL streptomycin and 
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maintained at 37
◦
C in a humidified atmosphere containing 5% CO2 as described 
previously (21).  
Treatments. N27 cells were pretreated with EGCG (100 μM) for 2 h, followed by 
6-OHDA (25 μM) treatment for 24 h. Untreated cells were used as controls. After 
treatments, cell lysate were collected used for the following assays.  
Measurement of intracellular ROS generation. The formation of intracellular 
ROS was measured by using a fluorescent probe, 2, 7-dichlorofluorescein diacetate as 
described previously (22, 23). The N27 cells were plated as the density of 2×10
4
 
cells/well on the 96-well plate. Medium was changed to HBSS before each treatment, 
and CM-H2DCFDA was added to final concentration with 10 μM to each well. The 
fluorescence intensity of dichlorofluorescein (DCF) was continuously measured using 
fluorescence spectrophotometer with excitation wavelength of 485 nm and emission 
wavelength of 535 nm with 30 min interval for 8 h. 
Thobartituric acid reactive substances (TBARS) assay. The TBARS assay was 
used to determine the lipid peroxidation and performed fluorometrically with a 
modified protocol (24). Briefly, cell lysates (200 μl) from different treatments were 
combined with ice cold 20% TCA (200 μl), and then incubated on ice for 5 min. 
Samples were centrifuged at 14,000 rpm at 4
◦
C for 5 min. Then 200 μl supernatant 
was mixed with 200 μl 0.67% (w/v) TBA reagent, and incubated at 95◦C for 60 min. 
Then 400 μl butanol/pyridine (15:1) was added to each sample and centrifuged at 
5,000 rpm for 5 min. The fluorescence intensity of malondialdehyde (MDA) in the 
upper butanol/pyridine phase was quantified with an excitation wavelength of 520 nm 
and emission wavelength of 550 nm on a black 96-well plate. 1, 1, 3, 
3-tetramethoxypropane was used as a standard to calculate the final sample 
concentration.  
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Protein Carbonyl Content (PCC) assay. The protein oxidation in the cell lysates 
samples were determined by measuring the PCC by using the DNPH 
(2,4-dinitrophenylhydrazine). According to the protocol provided by Cayman’s 
protein carbonyl assay kit (Ann Arbor, MI), the amount of protein-hydrozone product 
was quantified spectrophotometrically at wavelength of 363 nm on 96-well plate 
reader. Total protein content of cell lysates was determined by Pierce BCA protein 
assay kit (Rockford, IL). The PCC was calculated and normalized to the total protein 
content. 
Western blot analyses. After treatments described above, the N27 cells were 
washed with ice-cold PBS, then was homogenized in RIPA buffer (containing 1% 
Triton X-100, 0.1% SDS, 1 mM phenylmethanesulfonyl fluoride (PMSF) and 
protease inhibitors, including pepstatin 1 mg/ml, aprotinin 1 mg/ml, leupeptin 1 
mg/ml) and sonicated on ice 2 × 10 s. The supernatant was collected after maximum 
centrifugation at 13,000 rpm for 15 min at 4
◦
C. Aliquots of supernatants were used to 
measure the protein concentrations. Forty μg of protein was mixed with 5 × sample 
buffer (0.35 M Tris–Cl, 10% SDS, 30% glycerol, 0.012% bromophenol blue), and 
loaded onto a 12% or 15% SDS-polyacrylamide gel, electrophoresed and then 
transferred to a nitrocellulose membrane (Bio-Rad). The membrane was blocked with 
5% non-fat milk in TBST and then incubated with rabbit anti-rat Nrf2 polyclonal 
antibody (1:500), rabbit anti-rat HO-1 polyclonal antibody (1:500) or rabbit anti-rat 
PPARγ antibody (1:500), respectively. Horseradish peroxidase-conjugated goat 
anti-rat IgG antibody (1:3000, Santa Cruz, CA) was used as a secondary antibody. To 
ensure even loading of the protein samples, β-actin (1:1000) was used as internal 
control, with the incubation of the corresponding goat-anti-mouse-IgG-HRP 
secondary antibody (1:5000). All western blot assays were performed in triplicates. 
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Statistics analyses. Data were analyzed with Prism 4.0 software (Graph Software, 
San Diego, CA). All the measurements were normalized to the respective controls in 
each experiment. All values were expressed as mean ± SEM as percentage of the 
controls.  One-way ANOVA with Tukey’s multiple comparison test was used to 
detect the differences among treatments and P < 0.05 was considered as significant.  
 
Results 
EGCG attenuated ROS generation induced by 6-OHDA 
Intracellular ROS level was determined and shown in Figure 1. 6-OHDA increased 
intracellular ROS level by 19 % (p<0.001) after 6 h treatment, and by 33.1 % 
(p<0.001) after 8 h, compared to control group. Pretreatment of EGCG for 2 h 
following with 6-OHDA treatment reduced ROS by 24.9 % (p<0.001) at 6 h, and by 
31 % (p<0.001) at 8 h, compared to 6-OHDA treatment group; and reduced ROS by 
10.6% (p<0.05) at 6 h, and by 8.1% (p>0.05) at 8 h, compared to control. There was a 
decrease in ROS (14.3%, p<0.01) at 6 h, and (18.7%, p<0.001) at 8 h with EGCG 
alone compared with control group. Overall, EGCG pretreatment attenuated 6-OHDA 
induced ROS generation. 
 
EGCG protected against 6-OHDA-induced lipid peroxidation 
6-OHDA resulted in a marked increase (82.7%, p<0.001) in MDA concentration 
after 24 h treatment (Fig 2). Pretreatment of EGCG for 2 h decreased lipid 
peroxidation by 36.4% (p<0.001) compared to the 6-OHDA treatment. Although 
EGCG alone had lower (by 30.3%, p<0.01) MDA value than 6-OHDA + EGCG 
group, the value was not significant different compared to control.  
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EGCG protected against 6-OHDA-induced PCC 
As shown in Fig. 3, 6-OHDA increased the PCC by 47.8% (p<0.05) after 24 h 
treatment compared to the control. Pretreatment of EGCG for 2 h decreased the PCC 
by 27.7% (p<0.05), compared to 6-OHDA group. No difference between control and 
EGCG alone suggested there was no effect of EGCG on PCC. 
 
EGCG regulated antioxidant (Nrf2 and HO-1) and anti-inflammatory (PPARγ) 
system induced by 6-OHDA 
The activities of Nrf2, HO-1 and PPARγ were assessed and shown in Fig 4. 
6-OHDA increased Nrf2 by 69.6% (p<0.001), HO-1 by 173.3% (p<0.001) and 
PPARγ by 122.7% (p<0.001) after 24 h treatment, compared to control group. 
Pretreatment of EGCG for 2 h significantly decreased Nrf2 (by 36.7%, p<0.001), 
HO-1 (by 49.3%, p<0.001) and PPARγ (by 41.1%, p<0.01), compared to 6-OHDA 
group. Pretreatment of lower concentration of EGCG (10 μM) showed no decrease on 
HO-1 and PPARγ expression, but only significant decrease (by 18.9%, p<0.05) in 
Nrf2, compared to 6-OHDA group. Therefore, these results suggested high 
concentration of EGCG showed antioxidant and antiinflammation effects. 
 
Discussion 
6-OHDA is used as classical neurotoxin to induce neurodegneration and to 
understand the treatment of PD. The neurotoxicity of 6-OHDA has been proposed by 
several mechanisms, including free radicals damage, mitochondrial dysfunction, and 
oxidative stress (25). Since iron is involved in PD due to its pro-oxidant nature, the 
interruption of iron homeostasis by 6-OHDA causes neuronal damage. 6-OHDA can 
alter the expression of iron-related protein, resulting into iron dyshomeostasis (26, 27). 
94 
6-OHDA can cause iron release from cytosolic ferritin and increase intracellular free 
iron concentration (28). The excess free iron could generate ROS via Fenton reaction, 
causing oxidative stress and cell death, especially in the substantia nigra (29, 30). In 
our previous study, we showed that 6-OHDA regulated iron-related protein 
expression, increasing cellular iron uptake and retention in N27 cells. Here, we 
confirmed that 6-OHDA significantly increased the intracellular ROS level and 
oxidative damage to lipids and proteins in N27 cells. Therefore, iron dyshomeostasis 
is critical to cause neuronal cell death and maintaining normal iron level is important 
to prevent PD progression. 
In addition to oxidative stress, inflammation also plays a critical role in PD. It had 
been shown that neuroinflammation was significantly higher in PD brains, including 
numerous inflammation-related enzymes and cytokines within the SN, striatum, and 
cerebral spinal fluid. For example, tumor necrosis factors (TNF) and nitric oxide 
synthase (iNOS) were found significantly elevated in PD patients, compared to 
age-matched control (31). One of the proposed mechanisms of 6-OHDA toxicity is 
the induction of inflammation (32, 33). Inflammatory factors, such as TNFα could 
directly activate cell apoptotic pathway or indirectly suppress the mitochondrial 
function. Considerable evidence from in vitro and in vivo studies suggests that there is 
an association between inflammation and ROS in PD (34, 35), and increased ROS 
level could augment the inflammation process (36, 37), thereby exacerbating neuronal 
damage.  
Since oxidative stress and inflammation links to the progression of 
neurodegeneration, antioxidation and antiinflammation would be useful as 
neuroprevention strategies against PD. Nrf2/ARE system is considered a self-defense 
antioxidant system to counteract the increased ROS and oxidative stress. Increased 
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ROS levels and oxidative stress can trigger Nrf2 expression and Nrf2-associated 
antioxidant enzymes expression (38, 39). In the present study, we showed that 
6-OHDA increased not only ROS level, but also Nrf2 (by ~70%, p<0.001) and HO-1 
expression (by ~ 173%, p<0.001) in N27 cells. However, the increased antioxidant 
enzymes may not be enough to counteract the 6-OHDA toxicity, since we found 
elevated oxidative damage to lipid (by ~83%, p<0.001) and protein (by ~48%, 
p<0.05). Meanwhile, PPARγ was associated with the anti-inflammatory system to 
inhibit inflammatory reaction, increase DA, alter mitochondrial bioenergetics, reduce 
oxidative stress and impede PD progression (10). In our study, we found the 6-OHDA 
significantly increased PPARγ expression, which may indicate the increased 
inflammatory activity along with the increased ROS level. Similar to Nrf2, the 
increased PPARγ could not completely counteract against 6-OHDA toxicity, which 
may indicate the inadequate anti-inflammatory effect. Although the Nrf2/ARE 
antioxidant system is closely related to PPARγ antiinflammation system (40), whether 
there is a causal relationship remains unknown. Therefore, further research is needed 
to explore the relationship between Nrf2 and PPARγ. 
EGCG has been considered as an antioxidant to decrease oxidative stress and 
maintain the redox balance due to its high reduced potential and radical scavenging 
ability. As showed in Figure 1, EGCG significantly decreased ROS level even 
compared to the control group. EGCG is also considered as an iron chelator, therefore, 
it can also decrease the ROS by binding free iron without affecting the iron 
bioavailability. Several in vitro and in vivo studies have shown that EGCG treatment 
can prevent cancer, vascular diseases and neurological disorders (41, 42). We have 
previously shown that EGCG decreased iron uptake and retention in N27 cells and 
prevented against 6-OHDA neurotoxicity, which was supported by our results showed 
96 
that EGCG significantly reduced intracellular ROS, lipid peroxidation and protein 
carbonyls, which maybe attributed through iron accumulation. Several studies 
indicate EGCG can activate Nrf2 expression, which can induce antioxidant enzymes 
expression, improve antioxidant defense ability, such as HO-1(42-44). However, we 
were not able to show that EGCG increased either Nrf2 expression or PPARγ activity 
in our study. Both lower (10 μM) and higher (100 μM) concentration of EGCG 
showed no effects on Nrf2, HO-1 and PPARγ expression. One reason might be that 
EGCG directly decreased the ROS level by scavenging the free radicals or chelating 
excess iron. Therefore, the reduced ROS level and balanced redox potential would not 
activate Nrf2/ARE system and PPARγ activity. Another reason for the discrepancy of 
our results might be related to the difference of cell types. We used N27 cells which 
were much more sensitive to oxidative stress and complicated regulation pathways 
compared to non-neuronal cells.  
In conclusion, our in vitro data suggested that the neurotoxicity of 6-OHDA was 
closely related to ROS, oxidative stress and inflammation. Pretreatment of EGCG 
protected against 6-OHDA toxicity by inhibiting the ROS, consequently inactivating 
Nrf2, HO-1 and PPARγ expression. To our knowledge, this is the first in vitro study 
of EGCG on Nrf2 regulation to prevent 6-OHDA induced neurotoxicity. Further 
studies in vivo are needed to clarify the antioxidant and anti-inflammatory 
mechanisms of EGCG protection in PD.  
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FIGURE 1 EGCG attenuated 6-OHDA-induced intracellular ROS generation in N27 
cells. The fluorescence density showed in the time course of 6-OHDA increased ROS 
levels. The values are expressed as mean ±SEM, n=3. 6-OHDA (25 μM) was treated 
for 24 h, pretreatment of EGCG (100 μM) for 2 h. * p<0.001. 
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FIGURE 2 Effect of 6-OHDA and EGCG on lipid peroxidation. The values are 
expressed as mean ± SEM, n=2 from 3 individual measurements. Means with letters 
indicated comparison with control treatment. Symbols represented the comparison 
between treatments. 6-OHDA, 25 μM for 24 h, EGCG, 100 μM pretreatment for 2 h. 
* p<0.01, ** p<0.001. 
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FIGURE 3 Effect of EGCG on PCC induced by 6-OHDA. Cells were pretreated with 
EGCG, followed by 6-OHDA treatment. The values are expressed as mean ± SEM 
from duplicate measurements for 3 individual experiments. Labeled means without a 
common letter differ. 6-OHDA, 25 μM for 24 h, EGCG, 100 μM pretreatment for 2 h. 
* p<0.05.  
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FIGURE 4 Effects of 6-OHDA and EGCG on Nrf2, HO-1 and PPARγ protein 
expression. Cells were pretreated with EGCG, followed by 6-OHDA treatment. 
Western blot analysis (A) for Nrf2, HO-1and PPARγ protein expression (normalized 
with β-actin in N27 cells), and quantification analysis (B). The values were expressed 
as mean ± SEM from 4-8 individual measurements. Means with letters indicated 
comparison with control treatment. Symbols represented the comparison between 
treatments. 6-OHDA, 25 μM for 24 h, EGCG, 10, 100 μM pretreatment for 2 h.  
*p<0.05, **p<0.01, ***p<0.001. 
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CHAPTER 5. BENEFICAL EFFECTS OF GREEN TEA 
CONSUMPTION IN PARKINSON’S DISEASE PATIENTS 
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ABSTRACT: Antioxidants may offer protection on oxidative stress-associated 
Parkinson's disease (PD). The objective of this study was to assess the beneficial 
effect of green tea consumption (3 cups daily for 3 months) on quality of life, iron 
status, antioxidant status, and oxidative damage in PD patients. Fourteen subjects 
(51-79y) who were within the first five years of PD, on stable medication and not 
regular green tea consumers were recruited. PD rating scales were used to evaluate 
disease symptoms. Hemoglobin, serum iron, iron saturation and ferritin 
concentrations were used to assess the iron status. Antioxidant enzymes including 
catalase, superoxide dismutase (SOD), and glutathione peroxidase (GPx) were 
measured to determine the antioxidant status. Lipid peroxidation and protein 
carbonyls were used as oxidative damage markers. Wilcoxon matched pairs t-test and 
student t-test were used for statistical analysis between baseline and 3 month 
intervention data. Among the PD rating scales, we found a significant increase in 
Mini-Mental State Examination (MMSE) (p<0.05) and a decrease in United 
Parkinson's Disease Rating Scale (UPDRS) motor scores (p<0.05) after the 
intervention, suggesting an improvement in cognitive and motor status. No changes 
were found in iron status. Catalase and SOD activities were increased significantly 
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(28%, p<0.05 and 37%, p<0.01, respectively), indicating the improvement of 
antioxidant status. Both lipid peroxidation and protein carbonyls decreased by ~ 52% 
(p<0.01) after intervention. In conclusion, green tea consumption may slow down PD 
progression by improving the antioxidant status and reducing oxidative damages 
without affecting iron status.  
 
Key Words: Parkinson’s disease; antioxidant enzymes; oxidative stress; green tea 
consumption 
 
Parkinson’s disease (PD) is now considered the second most common 
neurodegenerative disorder after Alzheimer’s disease, affecting approximately 1 
percent of the population over 50 y.o. PD patients show classical motor symptoms 
including bradykinesia, rigidity, and resting tremors due to the depletion of dopamine 
in brain. Several factors, such as ageing, genetics, environment, oxidative stress, and 
inflammation are involved in PD progression. Among these factors, oxidative stress is 
one of the major causes in initiating and promoting neurodegeneration. Since brain 
tissue has high levels of polyunsaturated fatty acids, it is prone to oxidative damage. 
Excess iron accumulation in the brain leads to free radical formation and reactive 
oxygen species (ROS) generation via the Fenton reaction, contributing to oxidation 
damage of lipids and protein, and promoting cell death. Significant elevation of iron 
was found in the substantia nigra (SN) of PD patients compared to the age-matched 
control,
1, 2
 indicating the critical role of iron in PD progression. 
Antioxidants counteracting the detrimental effects of ROS offer a promising 
approach to protect neuronal cells. The antioxidant defense system is responsible for 
removing free radicals, scavenging ROS or their precursors, maintaining redox 
homeostasis, and decreasing oxidative damage.
3
 The antioxidant defense system can 
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be classified as exogenous (natural or synthetic), such as ascorbic acid, lipoic acids, 
polyphenols, and carotenoids, or endogenous, such as catalase, SOD, glutathione 
reductase (GSH), and glutathione peroxidase (GPx). Evidence has shown the 
beneficial effects of antioxidants in cell culture models.
4-7
 In vivo, higher levels of 
antioxidants are required to result in protective effects on the central nerve system 
(CNS), which is extremely sensitive to redox changes and oxidative dyshomeostasis 
due to the high level of oxidative metabolism. Insufficient antioxidants and 
antioxidant enzyme activities may not be able to offset the oxidative modifications 
and damages. Several studies indicate that increased oxidative damage and reduced 
antioxidant activities might be responsible for the onset and progression of PD.
8-10
 
Therefore, the activation of antioxidant enzymes is considered to be a necessary  
strategy to counteract the detrimental effects of ROS and restore the cellular redox 
balance.
11
 
Many antioxidants such as vitamin E, vitamin C, carotenoids, and flavonoids can 
improve antioxidant status and decrease oxidative stress, therefore preventing 
neurological disorders.
12-14
 Iron chelator, (i.e., desferrioxamine (DFO)) has shown 
neuroprotective effects in in vitro and in vivo studies.
15, 16
 However, the side effects of 
DFO limit its usefulness. Catechin polyphenols can act as antioxidants by scavenging 
free radicals and chelating excess metal ions.
17, 18
 They may also indirectly reducing 
oxidative stress inhibiting redox-sensitive transcription factors, nuclear factor-κB, and 
pro-oxidant enzymes, such as inducible nitric oxide synthase, and inducing phase II 
antioxidant enzymes, such as glutathione S-transferases and SOD. 
(-)-Epigallocatechin-3-Gallate (EGCG) is the most abundant polyphenol and iron 
chelator present in green tea,
19
 which has been shown to be an antioxidant in vitro by 
trapping peroxyl radicals and inhibiting lipid peroxidation, contributing to the 
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neuroprotective effects of green tea in several PD model cells.
20
 EGCG can better 
represent the antioxidant function of green tea in vivo, due to its bioavailability and 
metabolism. Higher green tea consumption is related to the reduced risk of PD
21-23
 
because it may offer a promising dietary source of neuroprotection. However, data 
showing whether or not green tea directly or indirectly improves the PD patients’ 
status is limited. The purpose of this study is to identify the beneficial effect of green 
tea consumption in PD patients. We hypothesized that green tea consumption may 
improve quality of life of PD patients by improving antioxidant status, thus, reducing 
oxidative damage to lipids and proteins. 
 
Patients and Methods 
Study Design and Participants 
Patients (n=15) (9 males, 6 females) were recruited from Parkinson’s disease and 
Movement Disorder Center at University of Kansas Medical Center (KUMC). The 
inclusion criteria included patients within the first five years of PD, aged between 50 
to 80 y, willing to drink green tea and were on stable medication regiment with no 
changes in medication throughout the study. The exclusion criteria included 
premenopausal women, Parkinsonism resulting from other causes including toxicity, 
drugs and head trauma, and patients with uncontrolled chronic diseases, smokers, and 
current green tea drinkers (> 3 cups/day). Subjects were provided with tea bags 
(Lipton
®
 100% Natural Green Tea) in batches at each visit and requested to drink 3 
cups of green tea per day (1 green tea bag steeped in 1 cup of boiling water for 4 
minutes).  
 
 
109 
Assessment of PD Status at Baseline and Post-intervention 
At baseline and at the 3 month visit, the United Parkinson's Disease Rating Scale 
(UPDRS) was completed to assess the PD-related disability and impairment. 39-item 
Parkinson’s disease questionnaire (PDQ-39) was used to assess the daily quality of 
life. Various other measures were used to evaluate PD symptoms, such as depression 
(Beck Depression Inventory), anxiety (Beck Anxiety Inventory), sleepiness (Epworth 
Sleepiness Scale), mental status (Mini Mental State Examination) and fatigue (Fatigue 
Severity Scale). Hoehn and Yahr (H&Y) scale was used to assess the stage of PD and 
Schwab and England Activities of Daily Living Scale (S&E) was used to test severity 
of the disease. All the questionnaires were included in the appendix 2. Blood was 
collected at baseline and 3 month intervention. The antioxidant enzyme activities in 
erythrocytes, including catalase, SOD, and GPx were determined by using 
commercial assay kits (Cayman Chemical Company, Ann Arbor, MI, USA). Serum 
ferritin was measured with RIA kit (Ramco Laboratories, Houston, TX, USA). 
Hemoglobin, serum iron saturation, and serum iron were determined by the 
commercial clinical laboratory (LabCrop, Kansas city, MO, USA). Serum 
malondialdehyde (MDA) concentration was estimated by thiobarbituric acid reactive 
substances (TBARS) assay and used to determine lipid peroxidation. Protein 
carbonyls in plasma were measured by using the commercial kits (Cayman Chemical 
Laboratories, Houston, TX, USA). 
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Statistical Analysis 
Wilcoxon matched pairs t-test was used to compare the changes in PD rating scales 
and student t-test was used to compare the changes in antioxidant enzymes, TBARS, 
protein carbonyls, and iron status between baseline and post-intervention. The mean 
differences between baseline and post-intervention were considered significant at 
p<0.05. 
 
Results 
Subject Description 
A total of 15 subjects were included in the study. One subject was withdrawn 
during the study period. The median of age of the14 subjects was 61y.o. with a range 
of 51 to 79y.o. Median BMI at baseline was 28.2 kg/m
2
 (overweight) with a BMI 
range of 18 kg/m
2
 to 41.8 kg/m
2
. At 3 months intervention, median BMI was 28.6 
kg/m
2
 (overweight) with a range of 18.5 kg/m
2
 to 45.6 kg/m
2
. Six of the subjects were 
classified as obese (BMI > 30 kg/m
2
) and the remaining 8 participants had a BMI 
between 18.5 kg/m
2
 to 28.7 kg/m
2 
following green tea consumption, classifying them 
as normal to overweight (BMI 18.5 kg/m
2
 to 29.9 kg/m
2
 ).  
 
Changes in PD Rating Scales 
The data from PD rating scales for all subjects are listed in Table 1. Values are 
expressed as mean + SD. Mean MMSE increased significantly (p<0.05) from 
29.5+0.7 to 29.9+0.4, indicating improved mental status following green tea 
consumption. The UPDRS motor exam score decreased significantly (p<0.05) from 
21.2+7.5 to 18.1+9.2, indicating an improvement in motor status. On the contrary, 
total activities of daily living (ADL) score from the UPDRS and the mobility score  
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from the PDQ-39 increased significantly (p<0.05) from 9.2+5.7 to 9.9+5.7, and from 
13.9+15 to 23.2+26.9 respectively, showing a decline in ability to perform ADL as 
well as mobility status. There were no changes in total UPDRS and total PDQ-39 
scores, suggesting the absence of change in PD symptoms and quality of life. There 
were also no changes in the H&Y scale score, S&E scale score, indicating no stage or 
severity changes in PD after green tea consumption. 
 
Changes in Iron Status 
Details of iron status are shown in Table 2. The values are expressed as mean + SD. 
No significant changes were found in hemoglobin, serum iron, iron saturation, and 
serum ferritin at baseline or post-intervention. At baseline and post-intervention, 
average hemoglobin concentration was 14.3+1.5 g/dL and 14.2+1.5 g/dL, average 
serum iron concentration was 85.9+28.5μg/dL and 87.5+38.2 μg/dL, average iron 
saturation was 25.1+8.7%, 26.5+12.6 %, and average ferritin concentration was 
61+50 ng/mL and 59+46 ng/mL. Overall, iron status was not affected by green tea 
consumption.   
 
Changes in Antioxidant Enzymes 
Compared to baseline, the mean activity of SOD in erythrocytes increased by 37% 
(p=0.0025) (Fig. 1A) post-intervention. Additionally, mean catalase activity increased 
by 28% (p=0.0483) (Fig. 1B). Although there was a 13% increase in the mean activity 
of GPx after green tea consumption, the change was not statistically significant 
(p>0.05) (Fig. 1C). Overall, antioxidant enzymes activities were improved following 
green tea consumption.  
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Changes in Oxidative Damage 
The mean value of MDA concentration decreased significantly (p<0.01) from 
2.5+0.9 μM to 1.2+0.8 μM after green tea consumption (Fig. 2A), indicating a 
decrease in lipid peroxidation. Protein carbonyl concentration also decreased 
significantly (p<0.01) from 0.82+0.21 nmol/mg to 0.39+0.27 nmol/mg (Fig. 2B), 
suggesting a decrease in protein damage.  
 
Discussion 
PD rating scales have been developed to measure the impact of PD on patients. 
These scales not only identify and monitor PD symptoms, but also assess severity and 
disease progression. Additionally, PD rating scales are useful for determining a 
patient’s eligibility for participation in research trials. UPDRS is the most commonly 
used scale to assess motor disability, motor impairment, mental dysfunction, and 
motor or non-motor complications. H&Y and S&E scales are commonly used to 
determine the PD stage and severity.
9
 PDQ-39 and other PD symptom measures, such 
as the MMSE, are also widely used PD rating scales. Our data indicated no change in 
total UPDRS score, total PDQ-39 score, and PD symptoms measures, (i.e., BDI, BAI), 
suggesting no disease progression following  green tea consumption. We found that 
there was approximately a 20% (p<0.05) decrease in motor examination scores and a 
significant (p<0.05) increase in MMSE, representing an improvement in motor 
abilities. There was no change in H&Y scale scores, as well as in S&E scale scores, 
suggesting no significant change in the stage or severity of PD. However, changes in 
total daily living score of UPDRS (~8%, p<0.05) and mobility score (~ 67%, p<0.05) 
of PDQ-39 may indicate a worsening of PD status. Our results conflict with various 
qualitative questionnaires used to assess PD status. In a recent study, motor 
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assessment was quantitatively evaluated by full-body motion capture data with a deep 
brain stimulator.
24
 This method enables us to devise more effective ways to track the 
progression of neurodegenerative movement disorders other than the currently used 
PD rating scales. Therefore, revising and designing new appropriate measurement 
scales can improve the evaluation on PD.
25
 
 Iron plays a critical role in CNS functioning and is closely related to the 
progression of neurodegenerative diseases. Excess iron can induce the ROS 
generation and cause oxidative damage once it overrides the biological detoxification 
ability. Significantly higher amount of iron in the brain were reported in PD patients 
compared to age-matched controls.
2, 26
 On the other hand, low circulating iron levels  
have also been reported in PD,
27
 suggesting iron deficiency or problems with iron 
storage in tissues such as liver and brain, thus, contributing to PD progression. In a 
study conducted by Qureshi (2006), it was shown that there was no change in serum 
iron levels, but a significantly higher level of iron in cerebrospinal fluid in PD patients, 
compared to a healthy control. 
28
 In our study, iron status values at the baseline were 
in the normal range and none of the values indicated iron deficiency anemia or iron 
excess. Although there is a concern that polyphenols can inhibit iron absorption and 
alter overall iron status, no changes in iron status after 3 months of green tea 
consumption was observed in our study. Our iron status results are similar to the iron 
status results reported in the previous study.
29
 Therefore, the iron relocation within 
specific regions in brain might become an important issue to trigger the progression of 
PD rather than affecting overall body iron status.  
Oxidative stress can cause dopaminergic cell death and neurodegeneration. 
Increased oxidative stress and decreased antioxidant enzymes have been shown in 
several human studies with PD patients.
8, 30, 31
 Since PD is related to oxidative stress 
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and iron accumulation in brain, maintaining normal iron homeostasis and enhancing 
antioxidant capabilities seem to be the ideal strategies to prevent PD. Green tea 
polyphenols are shown to prevent not only neurological diseases, but also cancer and 
inflammatory processes.
32-34
 EGCG is the main catechin component, contributing to 
the beneficial effects of green tea due to its iron chelation, antioxidant, and 
antiinflammation capabilities.
35
 EGCG has shown to protect neurotoxin-induced 
dopaminergic cell death in both in vitro and in vivo models.
36, 37
 EGCG is also found 
to enhance the activities of antioxidant enzymes, catalase, and SOD in the striatum of 
mice in a neurotoxin induced PD model.
38
 Our results support the previous studies, 
since green tea polyphenols demonstrated a protective effect in PD patients. Although 
iron status remained unaltered, there was a significant increase in catalase and SOD 
activity and a decrease in oxidative damage in lipids and proteins, suggesting that 
green tea polyphenols could potentially be used as therapeutic supplements. We 
believe that the beneficial effects are due to green tea consumption since patients did 
not change their medication use during the study and there was no indication of 
changes in dietary consumption during the 3 month trial period.  
Although epidemiological studies have shown a negative correlation between green 
tea consumption and the risk of neurological disorders including PD,
23, 39
 limited 
human data directly shows its effects against PD progression. A cross-sectional study 
indicated that inverse relationship between green tea consumption and cognitive 
impairment, but not cognitive decline, may be due to a small number of participants in 
the study.
39
 Chan (2009) showed that a green tea polyphenol (0.4 g, 0.8 g, and 1.2 g 
daily) intervention for early PD patients over a span of 6 months can improve UPDRS 
scores.
40
 In our study, participants consumed 3 cups of green tea daily for 3 months, 
with a total polyphenol concentration of approximately 550 mg per 3 tea bags . This 
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dosage resulted in an improvement in antioxidant status and reduced oxidative 
damage on PD patients after the 3-month intervention.  
One limitation of our study was the lack of an age-matched control group without 
PD and/or a control group including PD patients who didn’t consume green tea. 
During the 3-month green tea intervention, we did not find significant changes in the 
total UPDRS score, PDQ-39 score, and most of the PD measure scales, suggesting the 
need for a long-term study and a large group of PD patients. While we used a realistic, 
dietary approach to green tea consumption, using a purified EGCG supplement may 
prove to be more accurate for determining the beneficial effects on Parkinson’s 
disease patients in a future clinical study. Although our study had a few limitations, it 
also had several strengths. Our 3-month green tea intervention significantly improved 
antioxidant status and reduced oxidative damage in early PD patients without 
affecting their iron status. Based on this pilot study, a future study including a large 
number of subjects, the use of an EGCG supplement, and age-matched control group 
is needed to clarify the effectiveness of EGCG in preventing the progression of PD.  
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Figures and Tables 
 
TABLE 1. PD rating scales in subjects at baseline and after 3 mo green tea consumption 
 Mean (SD)                   Median (Range) 
   B           P                B             P 
PDQ-39   
Mobility * 
Activity of Daily Living  
Emotional well-being 
Stigma 
Social support 
Cognition 
Communication 
Bodily discomfort 
13.9 (15.0)   23.2 (26.9) 
17.6 (15.1)   20.2 (16.2) 
14.9 (11.2)   18.5 (21.8) 
20.5 (18.4)   22.8 (23.3) 
10.1 (15.4)   11.9 (19.0) 
15.2 (12.7)   14.7 (12.9) 
12.5 (15.2)   11.9 (17.2) 
32.1 (19.0)   25.6 (23.2) 
10 (0-45)       13.75 (0-67.5) 
16.7 (0-33.3)    22.9 (0-45.8) 
10.4 (0-33.3)    10.4 (0-66.7) 
18.8 (0-50)     18.8 (0-68.8) 
0 (41.7)        0 (0-58.3) 
12.5 (0-18.8)    12.5 (0-37.5) 
8.3 (0-41.7)     0 (0-50) 
25 (8.3-75)     20.8 (0-91.7) 
PDQ Total Score 16.4(11.5)   19.6(18.4) 15.7 (2.6-42.9)  15.4 (0.64-44.4) 
UPDRS  
Mentation, Mood, and Behavior 
Activities of Daily Living * 
Motor Examination * 
Total Score 
 
0.7 (1.2)      1.1 (1.6) 
9.2(5.7)      9.9(5.7) 
21.2(7.5)     18.1(9.2) 
31.1(12.6)    29(15) 
 
0 (0-4)         0 (0-5) 
9.5 (0-22)      10.5 (1-22) 
20 (8-38)       16 (6-38) 
31.5 (8-58)     26.5 (7-65) 
Beck Depression Inventory 7.1(5.8)      7.9(7.9) 5.5 (0-21)      5.5 (0-24) 
Beck anxiety inventory 10.3(6.7)     9.3(7.8) 9.5 (1-20)      9 (0-13) 
Epworth Sleepiness Scale 7.8(4.4)      7.7(5.1) 6.5 (3-17)      7 (4-16) 
Mini Mental State Examination 
* 
29.5(0.7)     29.9(0.4) 30 (28-30)     30 (29-30) 
Fatigue Severity Scale  28.4(13.0)    32.1(14.3) 27 (13-55)     30.5 (12-55) 
Wilcoxon matched pairs t-test is used to compare the changes on PD rating scales between baseline 
and post-intervention. Values are mean (SD) and median (range), n=14, * p<0.05. B, baseline; P, 
post-intervention.
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TABLE 2. Subject description and iron status at baseline and after 3 mo green tea consumption 
Subject 
# 
Height 
(M) 
Weight 
(Kg) 
BMI 
(Kg/M
2
) 
Hemoglobin 
(g/dL) 
Serum Iron 
(μg/dL) 
Iron Saturation 
(%) 
Serum Ferritin 
(ng/ml) 
B P B P B P B P B P B P 
Mean 
+ (SD) 
1.7 
(0.1) 
87 
(20.5) 
87.5 
(22.5) 
28.9 
(6.0) 
29.1 
(6.7) 
14.3 
(1.5) 
14.2 
(1.5) 
85.9 
(28.5) 
87.5 
(38.2) 
25.1 
(8.7) 
26.5 
(12.6) 
60.8 
(49.8) 
59.5 
(46.3) 
The height, weight, BMI and iron status values are expressed as mean + (SD), n=14. No significant changes were found in  
hemoglobin, serum iron, iron saturation and serum ferritin at baseline and post-intervention. B, baseline; P, post-intervention.
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         A                           B                          C 
FIG. 1. Antioxidant enzymes activities in erythrocytes at baseline and after 3 mo 
green tea consumption. (A) SOD, (B) catalase, (C) GPx. n=14, * p<0.05, ** p<0.01. 
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                A                                     B 
FIG. 2. Lipid peroxidation (A, measured as MDA concentration in serum) and protein 
damage (B, measured as protein carbonyl concentration in plasma) at baseline and 
after 3 mo green consumption. n=14, *p<0.01. 
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Appendix. PD Patients Demographic Data  
 
 
Subject 
# 
Age (Y) Gender PD Meds Con Meds 
1 53 F Sinemet 25/100 qid, Sinemet CR 50/200 qhs, 
Requip 3 mg tid 
Flexeril, Lorazepam, Cymbalta, Protonix, Benadryl, Melatonin 
2 68 M Stalevo 150 qid, Sinemet 25/100 qid, Mirapex 0.25 
mg qhs 
Zocor, MVI, ASA, Tramadol, Caltrate, Cal-Mag-Zn liquid, Vit D3, 
Magnesium 
3 55 F Azilect 1 mg qd, Mirapex 0.25 mg qd - bid, Stalevo 
50 qid 
MVI, Fish Oil, Flax seed, Calcium, Niacin, ASA, Glycolax powder, 
Glucosamine, CoQ10, 
4 66 M Sinemet 25/100 5.5 tabs/day Aricept, Wellbutrin, Alprazolam, Flomax, Advil, Tylenol 
5 57 M Azilect 1 mg qd, Requip 3 mg tid, Sinemet 25/100 
tid 
ASA 
6 51 M None Zocor, MVI, Vit D, ASA,CoQ10, Curcumin, Gingko Biloba, Fish Oil 
7 61 M Sinemet 25/100 2 tabs qid, Requip 3mg tid Evoxac, Synthroid, Simvastatin, Clonazepam, Zantac, MVI, Vit E, Fish 
Oil, Saw Palmetto 
8 67 F Sinemet 25/100 tid Lipitor, Toprol SL, HCTZ, Enalapril, Celebrex, Omeprazole, 
Gemfibrozil, Sertraline, Omega 3,  Calcium, ASA, Neurontin 
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Appendix. PD Patients Demographic Data (Continued) 
 
 
Subject 
# 
Age (Y) Gender PD Meds Con Meds 
9 66 F Azilect 1mg qd, Requip XL 8mg qd Simvastatin, Atenolol, Calcium +D, Fosamax 
10 54 F C/L 25/100 bid, Azilect 1 mg qd Altace, Prempro, Synthroid, Zoloft, Vytorin, Oxaprozin, Fish Oil, 
Women's MVI 
11 79 M Sinemet CR 50/200mg bid, Azilect 1 mg qd, 
Mirapex .5mg bid 
Oxycodone, Hydrocodone, HCTZ, Optiva, Lidoderm Patch, Detrol LA, 
Tylenol, Motrin 
12 56 M Sinemet 25/100mg qid, Mirapex 0.5mg tid Buspar, Remeron, Benicar, Azasite,  
13 59 M Sinemet 25/100mg tid, Requip 2mg tid, Azilect 
1mg qd 
Amlodipine, Pravastatin, Losartran HCTZ 
14 66 F Azilect 1mg qd  Claritin 24HR, Fosamax, Aleve, Simvastatin, ASA, Fish Oil, B12, 
Cranberry, Cal/mg/Zinc with D, Glucosamine CH, Multi Vit & Mineral, 
Biotin, D3 
15 66 M Selegiline 5 mg bid Actos, Multi-Vit, Fish Oil, Tylenol 
Median 
(range) 
 61 
(51~79) 
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CHAPTER 6. GENERAL CONCLUSION 
 
Parkinson’s disease (PD) is a progressive neurodegenerative disease causing severe 
dopamine depletion in the striatum. Numerous evidences indicated that iron played an 
important role in PD. Both in vitro and in vivo studies showed that excess iron was 
closely associated with neuronal cell damage. Interestingly, several neurotoxins, such 
as 6-OHDA can disrupt iron homeostasis by altering iron-related gene and protein 
expression, consequently induce iron accumulation, ROS generation, redox 
dyshomeostasis and oxidative stress. We also confirmed the irreversible oxidative 
damage to lipids and proteins. Therefore, maintaining iron homeostasis is a promising 
strategy to prevent PD.  
Results from epidemiological, cell culture, animal and clinical studies supported 
green tea polyphenols as well as the main constituent EGCG as neuroprevention 
methods to counteract neurodegeneration. In vitro study, pretreatment of EGCG 
showed more effective protection on neuronal cell against neurotoxin-induced cell 
damage than co-treatment, suggesting the preventive method is an effective protection 
on PD. It is also important to maintain the effective dosage of EGCG to show the 
neuroprotection. In this study, we showed EGCG at a concentration range of 10 μM 
-100 μM could protect neuron against 6-OHDA-induced cell apoptosis and cell death, 
whereas higher dosage (200 μM) was toxic to N27 cells and primary mesencephalic 
neuron. EGCG protected against 6-OHDA toxicity by decreasing DMT1, hepcidin, 
increasing Fpn1 expression and reducing cell iron uptake to maintain normal iron 
level. The pretreatment of EGCG suppressed the ROS generation and oxidative stress, 
attenuated lipid peroxdation and protein carbonyl, and decreased cell apoptosis and 
death.  
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Green tea consumption may offer a prospective dietary source of neuroprotection 
on PD patients. However, limited data showed green tea directly or indirectly 
improves the PD patients’ status. In our study, we have measured the PD patients’ 
blood EGCG concentration around 1.3 μM after consuming one bag of green tea with 
the bioavailability less than 1%. The participants daily consumed 3 cups of green tea 
for consecutive 3 months and this amount of green tea consumption showed an 
improved antioxidant status, reduced oxidative damage to lipid and protein, and a 
slow-down progression of PD without affecting the iron status. The poor 
bioavailability of EGCG is the concern for the effective concentration. Human study 
showed oral intake 20mg/kg body weight EGCG can cause plasma maximum 
concentration (Cmax) at 78 ng/ml (1). Animal studies showed that rat has only 1.6% 
bioavailability of EGCG, mice has relative higher, 26.5% (2, 3). The concentration is 
far below the micromolar concentration usually required in vitro activity. Therefore, 
modification of EGCG structure ((-)-EGCG octaacetate) is an effective way to 
improve the bioavailability, which has already been shown to inhibit breast tumor 
growth and prostate cancer in animal studies (4, 5).  
Future studies are still needed to clarify the mechanism on neuroprotection. In the 
first study, we showed EGCG reversed the adverse effects from 6-OHDA on iron 
related gene and protein expression. However, whether the oxidative stress affected 
the iron related factors, leading to the iron influx, or the influx of iron caused 
oxidative stress remains unclear. Also, whether the protection effect of EGCG directly 
depended on reducing oxidative stress, regulating the iron related factors, resulting in 
the decreased iron intake is still unclear. In the second study, we confirmed that 
Nrf2/ARE pathway, including HO-1 expression and PPARγ anti-inflammatory 
pathway were involved in the 6-OHDA induced neurotoxicity. We also showed that 
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Nrf2 positively related to PPARγ in neurodegeneration. However, whether there is a 
cause-effect relation remains unclear. In the third study, although we showed the 
beneficial effects of green tea consumption on PD patients, the improvement of health 
care, modern quality of life and other medication may also contribute to the changes 
and improve the PD status. Therefore, age-matched control is required in future 
human study.  
In conclusion, we showed the EGCG protection against 6-OHDA by normalizing 
its adverse effect on iron homeostasis in vitro. We also figure out the EGCG 
decreased the oxidative stress and inflammatory reaction which derived by 6-OHDA. 
These results are preliminary data for future in vivo study. The human study showed 
the beneficial effects of green tea consumption on PD patients, and this pilot human 
study added supportive data for future study, long-term and higher dosage, with 
modification on EGCG supplement will help us to clarify the therapeutic way to 
prevent PD.  
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